

A Systematic Review of the Prevalence of Schizophrenia

PLoS Medicine

2, e141

DOI: [10.1371/journal.pmed.0020141](https://doi.org/10.1371/journal.pmed.0020141)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Classification of Sociomedical Health Indicators: Perspectives for Health Administrators and Health Planners. <i>International Journal of Health Services</i> , 1976, 6, 521-538.	1.2	14
2	The Global Prevalence of Schizophrenia. <i>PLoS Medicine</i> , 2005, 2, e151.	3.9	226
3	The Genetics of Schizophrenia. <i>PLoS Medicine</i> , 2005, 2, e212.	3.9	228
4	Secondary Schizophrenia. <i>PLoS Medicine</i> , 2005, 2, e279.	3.9	4
5	Authors' Reply: Measurement Errors in Schizophrenia Epidemiology. <i>PLoS Medicine</i> , 2005, 2, e300.	3.9	1
6	Variations in the Incidence of Schizophrenia: Data Versus Dogma. <i>Schizophrenia Bulletin</i> , 2005, 32, 195-197.	2.3	126
7	The economic burden of schizophrenia in Canada in 2004. <i>Current Medical Research and Opinion</i> , 2005, 21, 2017-2028.	0.9	131
8	Management of Schizophrenia. <i>Disease Management and Health Outcomes</i> , 2006, 14, 107-125.	0.3	11
9	Analysis of High-Resolution HapMap of DTNBP1 (Dysbindin) Suggests No Consistency between Reported Common Variant Associations and Schizophrenia. <i>American Journal of Human Genetics</i> , 2006, 79, 903-909.	2.6	111
10	Is cannabis use psychotogenic?. <i>Lancet, The</i> , 2006, 367, 193-195.	6.3	44
11	Clinical and demographic features of treated first-episode psychotic disorders: A Zambian study. <i>Schizophrenia Research</i> , 2006, 86, 202-207.	1.1	21
12	What are the Policy Implications of the Evidence on Cannabis and Psychosis?. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 566-574.	0.9	41
13	What CALD consumers say about mental illness prevention. <i>Australian E-Journal for the Advancement of Mental Health</i> , 2006, 5, 126-131.	0.2	8
14	Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. <i>Psychological Medicine</i> , 2006, 36, 1535-1540.	2.7	141
15	Sex Selection Bias in Schizophrenia Antipsychotic Trials. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 489-494.	0.7	27
16	The incidence and prevalence of schizophrenia varies with latitude. <i>Acta Psychiatrica Scandinavica</i> , 2006, 114, 36-39.	2.2	80
17	Incidence of schizophrenia does not vary with economic status of the country. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2006, 41, 338-340.	1.6	37
18	Estrogen, Schizophrenia and Neurodevelopment. <i>Women's Health</i> , 2006, 2, 571-576.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Resolving the paradox of common, harmful, heritable mental disorders: Which evolutionary genetic models work best?. Behavioral and Brain Sciences, 2006, 29, 385-404.	0.4	495
20	Cross-cultural studies of personality traits and their relevance to psychiatry. Epidemiologia E Psichiatria Sociale, 2006, 15, 176-184.	1.0	38
21	Urbanicity and schizophrenia. From statistical association to causality?. Epidemiology and Psychiatric Sciences, 2006, 15, 239-241.	1.8	5
22	Urban birth and risk of schizophrenia: a worrying example of epidemiology where the data are stronger than the hypotheses. Epidemiology and Psychiatric Sciences, 2006, 15, 243-246.	1.8	41
23	Schizophrenia, Psychiatric Genetics, and Darwinian Psychiatry: An Evolutionary Framework. Schizophrenia Bulletin, 2007, 34, 722-733.	2.3	67
24	What Is the Best Approach to Treating Schizophrenia in Developing Countries?. PLoS Medicine, 2007, 4, e159.	3.9	37
25	Dissecting the Heterogeneity of Schizophrenia Outcomes. Schizophrenia Bulletin, 2007, 34, 247-248.	2.3	30
26	Cognitive Impairment in Schizophrenia: A Life Span Perspective. American Journal of Alzheimer's Disease and Other Dementias, 2007, 22, 398-405.	0.9	15
27	The Surprisingly Rich Contours of Schizophrenia Epidemiology. Archives of General Psychiatry, 2007, 64, 14.	13.8	90
28	Researching protective and promotive factors in mental health. International Journal of Epidemiology, 2007, 36, 703-707.	0.9	72
29	A Systematic Review of Mortality in Schizophrenia. Archives of General Psychiatry, 2007, 64, 1123.	13.8	1,770
30	Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population. Archives of General Psychiatry, 2007, 64, 19.	13.8	1,112
31	Influence of ethnicity on presentation and outcome of first episode psychosis. Irish Journal of Psychological Medicine, 2007, 24, 117-118.	0.7	0
32	Early prenatal stress impact on coping strategies and learning performance is sex dependent. Physiology and Behavior, 2007, 91, 55-65.	1.0	196
33	Antipsychotics inhibit TREK but not TRAAK channels. Biochemical and Biophysical Research Communications, 2007, 354, 284-289.	1.0	52
34	Coeliac disease and risk of schizophrenia and other psychosis: A general population cohort study. Scandinavian Journal of Gastroenterology, 2007, 42, 179-185.	0.6	49
35	The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland. Schizophrenia Research, 2007, 91, 27-36.	1.1	55
36	Schizophrenia. BMJ: British Medical Journal, 2007, 335, 91-95.	2.4	240

#	ARTICLE	IF	CITATIONS
37	Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. <i>Behavioral and Brain Functions</i> , 2007, 3, 34.	1.4	44
38	NCAM1 and Neurocognition in Schizophrenia. <i>Biological Psychiatry</i> , 2007, 61, 902-910.	0.7	80
39	Culture and schizophrenia. , 2007, , 314-322.		7
40	The European sertindole safety and exposure survey: a follow-up study of 8600 patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 804-811.	0.9	23
41	Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. <i>Molecular Psychiatry</i> , 2007, 12, 572-580.	4.1	255
42	Mental health nurses' experiences of schizophrenia rehabilitation in China and India: A preliminary study. <i>International Journal of Mental Health Nursing</i> , 2007, 16, 22-27.	2.1	11
43	Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 5-16.	2.2	28
44	Schizophrenia in Palau. <i>Current Anthropology</i> , 2007, 48, 189-213.	0.8	6
45	Psychometric evaluation of the Schizophrenia Quality of Life Scale (SQLS) in English- and Chinese-speaking Asians in Singapore. <i>Quality of Life Research</i> , 2008, 17, 115-122.	1.5	18
46	The need for culture sensitive diagnostic procedures. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 244-250.	1.6	40
47	Poverty, inequality and the treated incidence of first-episode psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 331-335.	1.6	62
48	Spatial analysis to identify hotspots of prevalence of schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 782-791.	1.6	22
49	The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe. <i>BMC Psychiatry</i> , 2008, 8, 57.	1.1	17
50	Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 686-696.	0.9	69
51	The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 425-433.	0.9	12
52	Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. <i>International Journal of Methods in Psychiatric Research</i> , 2008, 17, 55-61.	1.1	98
53	Biomarker discovery in psychiatric disorders. <i>Electrophoresis</i> , 2008, 29, 2884-2890.	1.3	33
54	Experiences of Asian American Parents in a Group Intervention for Youth With Schizophrenia. <i>Journal of Child and Adolescent Psychiatric Nursing</i> , 2008, 21, 220-227.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Genomewide association for schizophrenia in the CATIE study: results of stage 1. <i>Molecular Psychiatry</i> , 2008, 13, 570-584.	4.1	332
56	The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. <i>British Journal of Pharmacology</i> , 2008, 153, S133-6.	2.7	53
57	Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. <i>Molecular Psychiatry</i> , 2008, 13, 673-684.	4.1	91
58	The Cost-Effectiveness of Atypicals in the UK. <i>Value in Health</i> , 2008, 11, 1007-1021.	0.1	20
59	The Case for Autoimmunity in the Etiology of Schizophrenia. <i>Pharmacotherapy</i> , 2008, 28, 730-741.	1.2	50
60	Smoking status affects men and women differently on schizotypal traits and cognitive failures. <i>Personality and Individual Differences</i> , 2008, 44, 425-435.	1.6	8
61	Culture and schizophrenia. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 454-457.	0.2	4
62	The Prevalence of Mental Disorders among the Homeless in Western Countries: Systematic Review and Meta-Regression Analysis. <i>PLoS Medicine</i> , 2008, 5, e225.	3.9	758
63	Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1077-1107.	2.9	51
64	Schizophrenia, "Just the Facts": What we know in 2008. <i>Schizophrenia Research</i> , 2008, 100, 4-19.	1.1	298
65	Modelling disease frequency measures in schizophrenia epidemiology. <i>Schizophrenia Research</i> , 2008, 104, 246-254.	1.1	25
66	Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. <i>Schizophrenia Research</i> , 2008, 106, 337-347.	1.1	58
67	An association study of ADSS gene polymorphisms with schizophrenia. <i>Behavioral and Brain Functions</i> , 2008, 4, 39.	1.4	1
68	Epidemiological survey of mental disorders in the people aged 18 and older in Hebei Province. <i>Asian Journal of Psychiatry</i> , 2008, 1, 51-55.	0.9	23
69	The Evolutionary Persistence of Genes That Increase Mental Disorders Risk. <i>Current Directions in Psychological Science</i> , 2008, 17, 395-399.	2.8	22
70	The role of reelin in adult synaptic function and the genetic and epigenetic regulation of the reelin gene. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2008, 1779, 422-431.	0.9	77
71	Schizophrenia, "Just the Facts": What we know in 2008. 2. Epidemiology and etiology. <i>Schizophrenia Research</i> , 2008, 102, 1-18.	1.1	610
72	Prevalence and socio-demographic correlates of schizophrenia in Beijing, China. <i>Schizophrenia Research</i> , 2008, 102, 270-277.	1.1	55

#	ARTICLE	IF	CITATIONS
73	Adolescents and Adults with Autism with and without Co-morbid Psychiatric Disorders: Differences in Maternal Well-Being. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2008, 1, 53-74.	1.3	33
74	Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. <i>Epidemiologic Reviews</i> , 2008, 30, 67-76.	1.3	1,624
75	Negative symptoms in schizophrenia—A review. <i>Nordic Journal of Psychiatry</i> , 2008, 62, 334-341.	0.7	125
76	What a Tangled Web We Weave: Ethical and Legal Implications of Deception in Recruitment. <i>Accountability in Research</i> , 2008, 15, 262-282.	1.6	1
77	Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 1063.	1.0	28
78	The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. <i>Neuropsychopharmacology</i> , 2008, 33, 2061-2079.	2.8	183
79	Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. <i>Bulletin of the World Health Organization</i> , 2008, 86, 542-551.	1.5	81
80	Estimating the Prevalence of Schizophrenia Among New Zealand Māori: A Capture–Recapture Approach. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 941-949.	1.3	28
81	Psychotic-Like Ideations Among a Group of Young Normal Subjects in Iran. <i>International Journal of Social Psychiatry</i> , 2008, 54, 390-394.	1.6	4
82	Estimating Clinically Relevant Mental Disorders in a Rural and an Urban Setting in Postconflict Timor Leste. <i>Archives of General Psychiatry</i> , 2008, 65, 1205.	13.8	73
83	Problems and promise of immunological factors as biomarkers for schizophrenia. <i>Biomarkers in Medicine</i> , 2008, 2, 385-395.	0.6	3
84	The economic cost of schizophrenia in Ireland: a cost of illness study. <i>Irish Journal of Psychological Medicine</i> , 2008, 25, 80-87.	0.7	34
85	Schizophrenia in black Caribbeans living in the UK: an exploration of underlying causes of the high incidence rate. <i>British Journal of General Practice</i> , 2008, 58, 429-434.	0.7	45
86	Model-based gene selection shows engrailed 1 is associated with antipsychotic response. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 751-759.	0.7	14
87	Long-Term Efficacy and Safety of Iloperidone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S29-S35.	0.7	239
88	Utility of biomarkers to improve the diagnosis and treatment of schizophrenia. <i>Future Neurology</i> , 2008, 3, 619-622.	0.9	0
89	Introduction. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S1-S3.	0.7	3
90	Genomic Convergence Analysis of Schizophrenia: mRNA Sequencing Reveals Altered Synaptic Vesicular Transport in Post-Mortem Cerebellum. <i>PLoS ONE</i> , 2008, 3, e3625.	1.1	106

#	ARTICLE	IF	CITATIONS
91	Antipsychotics and risk of venous thromboembolism: A population-based case-control study. <i>Clinical Epidemiology</i> , 2009, 1, 19.	1.5	34
92	Population health surveys: An introduction to basic concepts. <i>International Journal of Therapy and Rehabilitation</i> , 2009, 16, 191-198.	0.1	0
93	New directions in the epidemiology of schizophrenia. <i>Medical Journal of Australia</i> , 2009, 190, S7-9.	0.8	68
94	Offenders with Mental Disorder on Five Continents: A Comparison of Approaches to Treatment and Demographic Factors Relevant to Measurement of Outcome. <i>International Journal of Forensic Mental Health</i> , 2009, 8, 81-96.	0.6	11
95	Improving Quality And Diffusing Best Practices: The Case Of Schizophrenia. <i>Health Affairs</i> , 2009, 28, 701-712.	2.5	45
96	A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results. <i>International Journal of Psychiatry in Clinical Practice</i> , 2009, 13, 138-146.	1.2	3
97	Approaches to psychiatric assessment in epidemiological studies of children. <i>Journal of Epidemiology and Community Health</i> , 2009, 63, i4-i14.	2.0	9
98	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1917-1928.	0.9	69
99	Evidence for a Role of the <i>NOS1AP (CAPON)</i> Gene in Schizophrenia and Its Clinical Dimensions: An Association Study in a South American Population Isolate. <i>Human Heredity</i> , 2009, 67, 163-173.	0.4	31
100	Packages of Care for Schizophrenia in Low- and Middle-Income Countries. <i>PLoS Medicine</i> , 2009, 6, e1000165.	3.9	65
101	Schizophrenia and Violence: Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2009, 6, e1000120.	3.9	826
102	How common are psychotic and bipolar disorders? A 50-year follow-up of the Lundby population. <i>Nordic Journal of Psychiatry</i> , 2009, 63, 336-346.	0.7	24
103	Relation of Schizophrenia Prevalence to Latitude, Climate, Fish Consumption, Infant Mortality, and Skin Color: A Role for Prenatal Vitamin D Deficiency and Infections?. <i>Schizophrenia Bulletin</i> , 2009, 35, 582-595.	2.3	104
104	Design and Clinical Characteristics of a Homogeneous Schizophrenia Pedigree Sample from Tamil Nadu, India. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 561-570.	1.3	9
105	Borderline Personality Disorder: Ontogeny of a Diagnosis. <i>American Journal of Psychiatry</i> , 2009, 166, 530-539.	4.0	224
106	Occupational therapy for people with psychotic conditions in community settings: a pilot randomized controlled trial. <i>Clinical Rehabilitation</i> , 2009, 23, 40-52.	1.0	45
107	Genomewide Association Studies: History, Rationale, and Prospects for Psychiatric Disorders. <i>American Journal of Psychiatry</i> , 2009, 166, 540-556.	4.0	391
108	Clinical Course and Outcome of Schizophrenia in a Predominantly Treatment-Naive Cohort in Rural Ethiopia. <i>Schizophrenia Bulletin</i> , 2009, 35, 646-654.	2.3	103

#	ARTICLE	IF	CITATIONS
109	Famine, death, and madness: Schizophrenia in early adulthood after prenatal exposure to the Chinese Great Leap Forward Famine. <i>Social Science and Medicine</i> , 2009, 68, 1315-1321.	1.8	101
110	Recent adaptive selection at <i>MAOB</i> and ancestral susceptibility to schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 369-374.	1.1	30
111	A common haplotype of <i>DRD3</i> affected by recent positive selection is associated with protection from schizophrenia. <i>Human Genetics</i> , 2009, 124, 607-613.	1.8	15
112	Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 395-412.	1.8	142
113	Personal Experience of Schizophrenia and the Role of Danwei: A Case Study in 1990s Beijing. <i>Culture, Medicine and Psychiatry</i> , 2009, 33, 86-111.	0.7	10
115	Metabolic risks in older adults receiving second-generation antipsychotic medication. <i>Current Psychiatry Reports</i> , 2009, 11, 33-40.	2.1	22
116	Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 143-150.	1.6	11
117	Mental health literacy of autism spectrum disorders in the Japanese general population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 651-657.	1.6	28
118	Prevalence and risk factors of psychotic symptoms: in the city of Izmir, Turkey. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 905-910.	1.6	29
119	Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients*. <i>International Journal of Clinical Practice</i> , 2009, 63, 1578-1588.	0.8	63
120	Generalized Anxiety Disorder in China: Prevalence, Sociodemographic Correlates, Comorbidity, and Suicide Attempts. <i>Perspectives in Psychiatric Care</i> , 2009, 45, 119-127.	0.9	33
121	Racial and Ethnic Disparities in the Treatment of a Medicaid Population with Schizophrenia. <i>Health Services Research</i> , 2009, 44, 2106-2122.	1.0	23
122	Association analysis of <i>COMT</i> polymorphisms with schizophrenia and smooth pursuit eye movement abnormality. <i>Journal of Human Genetics</i> , 2009, 54, 709-712.	1.1	27
123	Single- and Multiple-Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1318-1330.	1.0	32
124	What We Know: Findings That Every Theory of Schizophrenia Should Explain. <i>Schizophrenia Bulletin</i> , 2009, 35, 493-508.	2.3	117
125	Reconciling "the new epidemiology" with an evolutionary genetic basis for schizophrenia. <i>Medical Hypotheses</i> , 2009, 72, 353-358.	0.8	8
126	Psychose et migration, une revue de la littérature. <i>Annales Medico-Psychologiques</i> , 2009, 167, 459-463.	0.2	2
127	Evidence of Epistasis Between the Catechol-O-Methyltransferase and Aldehyde Dehydrogenase 3B1 Genes in Paranoid Schizophrenia. <i>Biological Psychiatry</i> , 2009, 65, 1048-1054.	0.7	38

#	ARTICLE	IF	CITATIONS
128	The prevalence and correlates of hallucinations in Australian adolescents: Results from a national survey. <i>Schizophrenia Research</i> , 2009, 107, 179-185.	1.1	102
129	Risk factors for suicide in schizophrenia: Findings from a Swedish population-based case-control study. <i>Schizophrenia Research</i> , 2009, 108, 231-237.	1.1	70
130	Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. <i>Current Medical Research and Opinion</i> , 2009, 25, 1593-1603.	0.9	8
131	Dissecting the Molecular Causes of Schizophrenia. <i>Nucleic Acids and Molecular Biology</i> , 2009, , 51-79.	0.2	1
132	lloperidone: a new option for the treatment of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1727-1741.	1.4	7
134	Schizophrenia: Epidemiology, Clinical Features, Course and Outcome. , 2009, , 453-458.		0
135	Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging. <i>Current Pharmaceutical Design</i> , 2009, 15, 2550-2559.	0.9	213
136	Schizophrenia in a worldwide perspective: explaining similarities and differences. <i>Future Neurology</i> , 2010, 5, 345-348.	0.9	0
137	Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts. <i>American Journal of Human Genetics</i> , 2010, 87, 316-324.	2.6	222
138	Systematic Reviews of Categorical Versus Continuum Models in Psychosis: Evidence for Discontinuous Subpopulations Underlying a Psychometric Continuum. Implications for DSM-V, DSM-VI, and DSM-VII. <i>Annual Review of Clinical Psychology</i> , 2010, 6, 391-419.	6.3	245
139	Social and clinical comparison between schizophrenia and bipolar disorder type I with psychosis in Costa Rica. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2010, 45, 675-680.	1.6	15
140	Aripiprazole in schizophrenia and schizoaffective disorder: A review. <i>Clinical Therapeutics</i> , 2010, 32, S3-S20.	1.1	86
141	Schizophrenia does not adversely affect the treatment of women with breast cancer: A cohort study. <i>Breast</i> , 2010, 19, 410-412.	0.9	25
142	Effect of Group Music Activity as an Adjunctive Therapy on Psychotic Symptoms in Patients With Acute Schizophrenia. <i>Archives of Psychiatric Nursing</i> , 2010, 24, 429-434.	0.7	37
143	Schizophrenia in Thailand: prevalence and burden of disease. <i>Population Health Metrics</i> , 2010, 8, 24.	1.3	32
144	Ethnic origin and increased risk for schizophrenia in immigrants to countries of recent and longstanding immigration. <i>Acta Psychiatrica Scandinavica</i> , 2010, 121, 325-339.	2.2	72
145	Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. <i>Molecular Psychiatry</i> , 2010, 15, 1088-1100.	4.1	108
146	Animal models of neuropsychiatric disorders. <i>Nature Neuroscience</i> , 2010, 13, 1161-1169.	7.1	1,762

#	ARTICLE	IF	CITATIONS
147	Reduced Fertility in Patients' Families Is Consistent with the Sexual Selection Model of Schizophrenia and Schizotypy. PLoS ONE, 2010, 5, e16040.	1.1	14
148	New atypical antipsychotics for schizophrenia: iloperidone. Drug Design, Development and Therapy, 2010, 4, 33.	2.0	39
149	Emerging treatments in the management of schizophrenia – focus on sertindole. Drug Design, Development and Therapy, 2010, 4, 187.	2.0	13
150	Positron Emission Tomography in Schizophrenia: A New Perspective. Journal of Nuclear Medicine, 2010, 51, 511-520.	2.8	55
151	Utilization of Public Mental Health Services in a Random Community Sample. Australian and New Zealand Journal of Psychiatry, 2010, 44, 475-481.	1.3	38
152	Appraising Evidence for Intervention Effectiveness in Early Psychosis: Conceptual Framework and Review of Evaluation Approaches. Australian and New Zealand Journal of Psychiatry, 2010, 44, 195-219.	1.3	16
153	Sensorimotor gating in NTS1 and NTS2 null mice: effects of <i>d</i>-amphetamine, dizocilpine, clozapine and NT69L. Journal of Experimental Biology, 2010, 213, 4232-4239.	0.8	12
154	Penetrance for copy number variants associated with schizophrenia. Human Molecular Genetics, 2010, 19, 3477-3481.	1.4	132
155	Endocannabinoids and Schizophrenia. Pharmaceuticals, 2010, 3, 3101-3126.	1.7	27
156	Comparison of DRD2 rs1800497 (TaqIA) polymorphism between schizophrenic patients and healthy controls: Lack of association in a Turkish sample. International Journal of Psychiatry in Clinical Practice, 2010, 14, 257-261.	1.2	9
157	Rates of Homicide During the First Episode of Psychosis and After Treatment: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2010, 36, 702-712.	2.3	203
158	Psychiatric Genocide: Nazi Attempts to Eradicate Schizophrenia. Schizophrenia Bulletin, 2010, 36, 26-32.	2.3	44
159	Borderline Personality Disorder: Ontogeny of a Diagnosis. Focus (American Psychiatric Publishing), 2010, 8, 230-239.	0.4	3
160	Schizophrenia in the Offspring of Antenatally Depressed Mothers in the Northern Finland 1966 Birth Cohort: Relationship to Family History of Psychosis. American Journal of Psychiatry, 2010, 167, 70-77.	4.0	58
161	Discovery of 4-(5-Methyloxazo[4,5- <i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel ± 7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models. Journal of Medicinal Chemistry, 2010, 53, 1222-1237.	2.9	68
162	Prevalence of DSM-IV major mental disorders among Korean adults: A 2006 National Epidemiologic Survey (KECA-R). Asian Journal of Psychiatry, 2010, 3, 26-30.	0.9	70
163	Replication of Association Between Working Memory and Reelin, a Potential Modifier Gene in Schizophrenia. Biological Psychiatry, 2010, 67, 983-991.	0.7	58
164	Schizophrenia and the city: A review of literature and prospective study of psychosis and urbanicity in Ireland. Schizophrenia Research, 2010, 116, 75-89.	1.1	164

#	ARTICLE	IF	CITATIONS
165	Where have all the women gone?. Schizophrenia Research, 2010, 119, 240-245.	1.1	51
166	Preliminary findings from a study of first-episode psychosis in Montreal, Canada and Chennai, India: Comparison of outcomes. Schizophrenia Research, 2010, 121, 227-233.	1.1	46
167	A unifying hypothesis of schizophrenia: Abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Medical Hypotheses, 2010, 74, 555-563.	0.8	85
168	An exploratory model for GÃ—E interaction on hippocampal volume in schizophrenia; obstetric complications and hypoxia-related genes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1259-1265.	2.5	35
169	Disentangling the attentional deficit in schizophrenia: Pointers from schizotypy. Psychiatry Research, 2010, 176, 143-149.	1.7	32
170	Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Research, 2010, 179, 147-150.	1.7	44
171	Acetylcholineâ€“Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders. CNS Neuroscience and Therapeutics, 2010, 16, 137-162.	1.9	164
172	The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia11The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMEA or one of its committees or working parties or the BfArM.. European Neuropsychopharmacology, 2010, 20, 139-145.	0.3	11
173	Narrowing the Boundaries of the Genetic Architecture of Schizophrenia. Schizophrenia Bulletin, 2010, 36, 14-23.	2.3	100
174	Global Issues in Mental Health Across the Life Span: Challenges and Nursing Opportunities. Nursing Clinics of North America, 2010, 45, 501-519.	0.7	12
175	Exploring the apparent absence of psychosis amongst the Borana pastoralist community of Southern Ethiopia. A mixed method follow-up study. World Psychiatry, 2010, 9, 98-102.	4.8	18
176	Overview sulla scarsa aderenza al trattamento farmacologico nei pazienti schizofrenici e stima del fenomeno a livello delle Regioni italiane. Giornale Italiano Di Health Technology Assessment, 2011, 4, 33-40.	0.1	0
177	HLA-DRB1 association with schizophrenia in Saudi Arabian patients. International Journal of Psychiatry in Clinical Practice, 2011, 15, 112-117.	1.2	14
178	Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2011, 25, 567-620.	2.0	332
180	Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe. European Psychiatry, 2011, 26, 17-28.	0.1	20
181	Evidence of Sex-Modulated Association of ZNF804A with Schizophrenia. Biological Psychiatry, 2011, 69, 914-917.	0.7	57
182	Converging evidence of blood-based biomarkers for schizophrenia. International Review of Neurobiology, 2011, 101, 95-144.	0.9	47
183	Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert Review of Neurotherapeutics, 2011, 11, 1541-1552.	1.4	12

#	ARTICLE	IF	CITATIONS
184	Incidence of adult onset schizophrenic disorders in the US Military: Patterns by sex, race and age. <i>Schizophrenia Research</i> , 2011, 127, 235-240.	1.1	16
185	Association of an <i>UCP4</i> (SLC25A27) haplotype with ultra-resistant schizophrenia. <i>Pharmacogenomics</i> , 2011, 12, 185-193.	0.6	23
186	Relationships between pre-stimulus gamma power and subsequent P300 and reaction time breakdown in schizophrenia. <i>International Journal of Psychophysiology</i> , 2011, 79, 16-24.	0.5	40
187	No association between the <i>KCNH1</i> , <i>KCNJ10</i> and <i>KCNN3</i> genes and schizophrenia in the Han Chinese population. <i>Neuroscience Letters</i> , 2011, 487, 61-65.	1.0	4
188	The environment and susceptibility to schizophrenia. <i>Progress in Neurobiology</i> , 2011, 93, 23-58.	2.8	539
189	Association study between <i>GNB1L</i> and three major mental disorders in Chinese Han populations. <i>Psychiatry Research</i> , 2011, 187, 457-459.	1.7	12
190	Development and validation of the Intellectual Disability Literacy Scale for assessment of knowledge, beliefs and attitudes to intellectual disability. <i>Research in Developmental Disabilities</i> , 2011, 32, 1530-1541.	1.2	43
191	Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. <i>Pharmacogenomics</i> , 2011, 12, 351-363.	0.6	36
192	A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. <i>Schizophrenia Research</i> , 2011, 133, 133-142.	1.1	130
193	What are the policy implications of the evidence on cannabis and psychosis?. , 0, , 55-65.		1
194	Pharmacotherapy for treatment-resistant schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 135.	1.0	52
195	Family therapy for schizophrenia: cultural challenges and implementation barriers in the South African context. <i>African Journal of Psychiatry</i> , 2011, 14, 367-71.	0.1	13
196	Using an Uncertainty-Coding Matrix in Bayesian Regression Models for Haplotype-Specific Risk Detection in Family Association Studies. <i>PLoS ONE</i> , 2011, 6, e21890.	1.1	3
197	Increased Risks of Acute Organ Dysfunction and Mortality in Intensive Care Unit Patients With Schizophrenia. <i>Psychosomatic Medicine</i> , 2011, 73, 620-626.	1.3	29
198	Symptoms of Schizophrenia and Psychosis According to Foreign Birth in a Canadian Sample of Homeless Persons. <i>Psychiatric Services</i> , 2011, 62, 1187-1193.	1.1	11
199	Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. <i>Epidemiology and Psychiatric Sciences</i> , 2011, 20, 317-327.	1.8	60
200	Prevalence of delusional disorder among psychiatric inpatients: data from the German hospital register. <i>Neuropsychiatry</i> , 2011, 1, 319-323.	0.4	3
201	Evolutionary Theories of Depression: A Critical Review. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 716-726.	0.9	79

#	ARTICLE	IF	CITATIONS
202	A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 98-106.	2.2	121
203	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i>Molecular Psychiatry</i> , 2011, 16, 76-85.	4.1	141
204	A systematic review of the global distribution and availability of prevalence data for bipolar disorder. <i>Journal of Affective Disorders</i> , 2011, 134, 1-13.	2.0	83
205	The Meaning of Community Rehabilitation for Schizophrenia Patients in Israel. <i>Community Mental Health Journal</i> , 2011, 47, 351-360.	1.1	6
206	Incidence of hospitalised schizophrenia in Finland since 1980: decreasing and increasing again. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 343-350.	1.6	19
207	Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. <i>Psychopharmacology</i> , 2011, 216, 579-587.	1.5	6
208	Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. <i>Psychopharmacology</i> , 2011, 218, 733-748.	1.5	15
209	Transgenic mice overexpressing the extracellular domain of NCAM are impaired in working memory and cortical plasticity. <i>Neurobiology of Disease</i> , 2011, 43, 372-378.	2.1	36
210	Pathway-based analysis for genome-wide association studies of schizophrenia to provide new insight in schizophrenia study. <i>Science Bulletin</i> , 2011, 56, 3398-3402.	1.7	2
211	An Update on the Epidemiology of Schizophrenia with a Special Reference to Clinically Important Risk Factors. <i>International Journal of Mental Health and Addiction</i> , 2011, 9, 39-59.	4.4	7
212	Three models of community mental health services In low-income countries. <i>International Journal of Mental Health Systems</i> , 2011, 5, 3.	1.1	54
213	Developments in schizophrenia genetics: From linkage to microchips, deletions and duplications. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 82-88.	0.7	6
214	Prior psychiatric inpatient care and risk of cesarean sections: a registry study. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2011, 32, 189-197.	1.1	12
215	The Prevalence of Delusion-Like Beliefs Relative to Sociocultural Beliefs in the General Population. <i>Psychopathology</i> , 2011, 44, 106-115.	1.1	54
216	Clozapine Use in Australia. <i>Australasian Psychiatry</i> , 2011, 19, 175-175.	0.4	13
217	The nature, frequency and course of psychiatric disorders in the first year after traumatic brain injury: a prospective study. <i>Psychological Medicine</i> , 2011, 41, 2099-2109.	2.7	170
218	Association of VSNL1 with schizophrenia, frontal cortical function, and biological significance for its gene product as a modulator of cAMP levels and neuronal morphology. <i>Translational Psychiatry</i> , 2011, 1, e22-e22.	2.4	28
219	Oxidative Stress in Schizophrenia: Pathogenetic and Therapeutic Implications. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1999-2002.	2.5	67

#	ARTICLE	IF	CITATIONS
220	Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. <i>Current Medical Research and Opinion</i> , 2011, 27, 115-122.	0.9	14
221	Provision and practice of art therapy for people with schizophrenia: Results of a national survey. <i>Journal of Mental Health</i> , 2011, 20, 328-335.	1.0	25
223	Ethical Considerations and Risks in Psychiatric Genetics: Preliminary Findings of a Study on Psychiatric Genetic Researchers. <i>American Journal of Bioethics Primary Research</i> , 2011, 2, 52-60.	1.5	7
224	Global assessment of psychosocial functioning and predictors of outcome in schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 62-68.	1.2	14
225	Runs of Homozygosity Implicate Autozygosity as a Schizophrenia Risk Factor. <i>PLoS Genetics</i> , 2012, 8, e1002656.	1.5	109
226	Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. <i>Bulletin of the World Health Organization</i> , 2012, 90, 47-54B.	1.5	147
227	Cultural Aspects of Major Mental Disorders: A Critical Review from an Indian Perspective. <i>Indian Journal of Psychological Medicine</i> , 2012, 34, 306-312.	0.6	43
228	Family History of Schizophrenia and Bipolar Disorder as Risk Factors for Autism. <i>Archives of General Psychiatry</i> , 2012, 69, 1099-1103.	13.8	215
229	Managing Depression in Countries With Low and Middle Incomes. <i>Psychosomatic Medicine</i> , 2012, 74, 880-881.	1.3	1
230	Randomized Trial to Evaluate the Efficacy of Cognitive Therapy for Low-Functioning Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 2012, 69, 121.	13.8	292
231	The Effect of Race-Ethnicity and Geography on Adoption of Innovations in the Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2012, 63, 1171-1177.	1.1	9
232	Cerebral cortical development in rodents and primates. <i>Progress in Brain Research</i> , 2012, 195, 45-70.	0.9	107
233	Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. <i>Molecular Psychiatry</i> , 2012, 17, 827-840.	4.1	210
234	Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 612-619.	1.3	23
235	The Continuum of Psychotic Symptoms in the General Population: A Cross-national Study. <i>Schizophrenia Bulletin</i> , 2012, 38, 475-485.	2.3	266
236	Specialist interventions for homeless people with severe mental illness. <i>The Cochrane Library</i> , 2012, , .	1.5	1
238	Retrospective: Julian Jaynes and The Origin of Consciousness in the Breakdown of the Bicameral Mind. <i>American Journal of Psychology</i> , 2012, 125, 369.	0.5	0
239	From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments. <i>Current Pharmaceutical Design</i> , 2012, 18, 459-465.	0.9	51

#	ARTICLE	IF	CITATIONS
240	Retrospective: Julian Jaynes and The Origin of Consciousness in the Breakdown of the Bicameral Mind. American Journal of Psychology, 2012, 125, 95.	0.5	4
241	Quetiapine versus placebo for schizophrenia. The Cochrane Library, 2012, , .	1.5	5
242	Adjuvant chemotherapy for breast cancer in patients with schizophrenia. Oncology Letters, 2012, 3, 845-850.	0.8	17
243	Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment. Focus (American Psychiatric Publishing), 2012, 10, 140-153.	0.4	11
244	Genetics of schizophrenia from a clinical perspective. International Review of Psychiatry, 2012, 24, 393-404.	1.4	10
245	Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 1775-1782.	1.6	46
246	Sex steroids and schizophrenia. Reviews in Endocrine and Metabolic Disorders, 2012, 13, 187-207.	2.6	108
247	The chromosome 15q14 locus for bipolar disorder and schizophrenia: Is C15orf53 a major candidate gene?. Journal of Psychiatric Research, 2012, 46, 1414-1420.	1.5	4
248	Two de novo mutations of MFN2 associated with early-onset Charcot-Marie-Tooth disease type 2A neuropathy. Genes and Genomics, 2012, 34, 653-661.	0.5	3
249	Schizophrenia Spectrum Disorders in Later Life: Prevalence and Distribution of Age at Onset and Sex in a Dutch Catchment Area. American Journal of Geriatric Psychiatry, 2012, 20, 18-28.	0.6	84
250	Schooling Students with Psychotic Disorders. Child and Adolescent Psychiatric Clinics of North America, 2012, 21, 187-200.	1.0	3
252	Methodology and reporting of systematic reviews and meta-analyses of observational studies in psychiatric epidemiology: Systematic review. British Journal of Psychiatry, 2012, 200, 446-453.	1.7	38
253	Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-<i>O</i>-methyltransferase Inhibitors and Substrates. ACS Chemical Neuroscience, 2012, 3, 129-140.	1.7	35
254	Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Molecular Psychiatry, 2012, 17, 880-886.	4.1	230
255	Association of intron 1 variants of the dopamine transporter gene with schizophrenia. Neuroscience Letters, 2012, 513, 137-140.	1.0	10
256	Risperidone interacts with serum albumin forming complex. Environmental Toxicology and Pharmacology, 2012, 33, 262-266.	2.0	9
257	<i>ZNF804A</i> and schizophrenia susceptibility in Asian populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 794-802.	1.1	30
258	The C allele of synonymous SNP (rs1142636, Asn170Asn) in <i>SYN1</i> is a risk factor for the susceptibility of Korean female schizophrenia. Synapse, 2012, 66, 979-983.	0.6	3

#	ARTICLE	IF	CITATIONS
259	Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. <i>Population Health Metrics</i> , 2012, 10, 16.	1.3	28
260	Paradox of schizophrenia genetics: is a paradigm shift occurring?. <i>Behavioral and Brain Functions</i> , 2012, 8, 28.	1.4	6
261	Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?. <i>International Journal of Mental Health Systems</i> , 2012, 6, 9.	1.1	10
262	Schizophrenia shows a unique metabolomics signature in plasma. <i>Translational Psychiatry</i> , 2012, 2, e149-e149.	2.4	138
263	Blood-brain barrier dysfunction in brain diseases: Clinical experience. <i>Epilepsia</i> , 2012, 53, 7-13.	2.6	57
264	Epidemiology of schizophrenia – An update with a focus on developing countries. <i>International Review of Psychiatry</i> , 2012, 24, 387-392.	1.4	24
265	Evolution of the Concept of Treatment-resistant Schizophrenia: Toward a Reformulation for Lack of an Adequate Response. <i>Journal of Experimental and Clinical Medicine</i> , 2012, 4, 98-102.	0.2	9
266	Stimulus-Selective Response Plasticity in the Visual Cortex: An Assay for the Assessment of Pathophysiology and Treatment of Cognitive Impairment Associated with Psychiatric Disorders. <i>Biological Psychiatry</i> , 2012, 71, 487-495.	0.7	73
267	Five-year clinical course and outcome of schizophrenia in Ethiopia. <i>Schizophrenia Research</i> , 2012, 136, 137-142.	1.1	23
268	Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. <i>Schizophrenia Research</i> , 2012, 139, 237-245.	1.1	63
269	Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far?. <i>Schizophrenia Research</i> , 2012, 140, 204-213.	1.1	129
270	Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia. <i>Schizophrenia Research</i> , 2012, 141, 262-265.	1.1	13
272	Drug safety and efficacy evaluation of sertindole for schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 1047-1062.	1.0	13
273	Human genetics of schizophrenia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 37-52.	1.0	4
274	Impairments of Social Motor Coordination in Schizophrenia. <i>PLoS ONE</i> , 2012, 7, e29772.	1.1	101
275	Genome-Wide Association Study of Treatment Refractory Schizophrenia in Han Chinese. <i>PLoS ONE</i> , 2012, 7, e33598.	1.1	55
276	The Role of Primary Care in Service Provision for People with Severe Mental Illness in the United Kingdom. <i>PLoS ONE</i> , 2012, 7, e36468.	1.1	118
277	Experiences of Domestic Violence and Mental Disorders: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e51740.	1.1	479

#	ARTICLE	IF	CITATIONS
278	DISC1 and Striatal Volume: A Potential Risk Phenotype For mental Illness. <i>Frontiers in Psychiatry</i> , 2012, 3, 57.	1.3	13
279	Genomics of Behavioral Diseases. <i>Frontiers in Genetics</i> , 2012, 3, 45.	1.1	6
280	A Comparative, Developmental, and Clinical Perspective of Neurobehavioral Sexual Dimorphisms. <i>Frontiers in Neuroscience</i> , 2012, 6, 84.	1.4	24
281	Uptake and knowledge of voting rights by adult in-patients during the 2010 UK general election. <i>The Psychiatrist</i> , 2012, 36, 126-130.	0.3	10
282	Emotions, Traits and Negative Beliefs as Possible Mediators in the Relationship between Childhood Experiences of being Bullied and Paranoid Thinking in a Non-Clinical Sample. <i>Journal of Experimental Psychopathology</i> , 2012, 3, 624-638.	0.4	13
283	Critical appraisal of lurasidone in the management of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 155.	1.0	29
284	Psychosis in Indigenous populations of Cape York and the Torres Strait. <i>Medical Journal of Australia</i> , 2012, 196, 133-135.	0.8	33
285	Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 179-186.	0.7	39
286	No evidence that major mtDNA European haplogroups confer risk to schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 414-421.	1.1	25
287	Investigation of allelic heterogeneity of the CCK ϵ receptor gene in paranoid schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 741-747.	1.1	10
288	Treatment prevalence and incidence of schizophrenia in Quebec using a population health services perspective: different algorithms, different estimates. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 533-543.	1.6	48
289	Association Between a Casein Kinase 1 Epsilon Gene Polymorphism and Schizophrenia in a Chinese Han Population. <i>Journal of Molecular Neuroscience</i> , 2012, 47, 470-474.	1.1	14
290	Rare and common variants: twenty arguments. <i>Nature Reviews Genetics</i> , 2012, 13, 135-145.	7.7	1,077
291	Meta-analysis indicates that common variants at the DISC1 locus are not associated with schizophrenia. <i>Molecular Psychiatry</i> , 2012, 17, 634-641.	4.1	69
292	Identification of a biological signature for schizophrenia in serum. <i>Molecular Psychiatry</i> , 2012, 17, 494-502.	4.1	189
293	Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 235-239.	1.0	44
294	Predicting the likelihood of suicide attempts for rural outpatients with schizophrenia. <i>Journal of Clinical Nursing</i> , 2012, 21, 2896-2904.	1.4	6
295	Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 247-260.	1.0	49

#	ARTICLE	IF	CITATIONS
296	The development of a lay health worker delivered collaborative community based intervention for people with schizophrenia in India. <i>BMC Health Services Research</i> , 2012, 12, 42.	0.9	125
297	Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model. <i>Journal of Neuroinflammation</i> , 2012, 9, 56.	3.1	66
298	Risk of psychiatric treatment for mood disorders and psychotic disorders among migrants and Dutch nationals in Utrecht, The Netherlands. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 271-278.	1.6	43
299	The mental health system in Lombardy, Italy: access to services and patterns of care. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 447-454.	1.6	36
300	The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 95-106.	1.0	47
301	Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 1357-1365.	1.6	25
302	Socio demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal. <i>BMC Psychiatry</i> , 2013, 13, 96.	1.1	18
303	Functional dysconnectivity in schizophrenia and its relationship to neural synchrony. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 755-765.	1.4	18
304	Genome-wide association analysis identifies 13 new risk loci for schizophrenia. <i>Nature Genetics</i> , 2013, 45, 1150-1159.	9.4	1,395
305	Neurodevelopmental Genomics of Autism, Schizophrenia, and Related Disorders. , 2013, , 695-708.		0
306	Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1575-1586.	6.3	4,651
307	Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1564-1574.	6.3	668
308	Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2013, 47, 670-677.	1.5	129
309	Awareness of schizophrenia and intellectual disability and stigma across ethnic groups in the UK. <i>Psychiatry Research</i> , 2013, 208, 125-130.	1.7	26
310	Dendritic spine pathology in schizophrenia. <i>Neuroscience</i> , 2013, 251, 90-107.	1.1	472
311	Exploring genomics: The way forward in curbing schizophrenia. <i>Clinical Epidemiology and Global Health</i> , 2013, 1, 142.	0.9	0
312	Do sleep abnormalities and misaligned sleep/circadian rhythm patterns represent early clinical characteristics for developing psychosis in high risk populations?. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2631-2637.	2.9	53
313	Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7612-7623.	1.4	28

#	ARTICLE	IF	CITATIONS
314	The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants. <i>Molecular Psychiatry</i> , 2013, 18, 38-52.	4.1	75
315	Breast cancer in patients with schizophrenia. <i>American Journal of Surgery</i> , 2013, 206, 798-804.	0.9	43
316	Genetic variants in transforming growth factor- β gene (TGFB1) affect susceptibility to schizophrenia. <i>Molecular Biology Reports</i> , 2013, 40, 5607-5614.	1.0	45
317	Management of schizophrenia: clinical experience with asenapine. <i>Journal of Psychopharmacology</i> , 2013, 27, 14-22.	2.0	10
319	Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. <i>BMC Psychiatry</i> , 2013, 13, 221.	1.1	69
320	Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: protocol for a systematic review. <i>Systematic Reviews</i> , 2013, 2, 112.	2.5	7
321	The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia. <i>Advances in Pharmacology</i> , 2013, 68, 199-220.	1.2	16
322	Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. <i>Journal of Medical Economics</i> , 2013, 16, 231-239.	1.0	57
323	Influence of latent <i>Toxoplasma</i> infection on human personality, physiology and morphology: pros and cons of the <i>Toxoplasma</i> "human model in studying the manipulation hypothesis. <i>Journal of Experimental Biology</i> , 2013, 216, 127-133.	0.8	205
324	A combined study of genetic association and brain imaging on the <i>DAOA</i> gene in schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 191-200.	1.1	12
325	A Systematic Review and Meta-Analysis of Recovery in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 1296-1306.	2.3	674
326	Comparative study of regional homogeneity in schizophrenia and major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 36-43.	1.1	39
327	New Perspectives on Late-Life Psychosis. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 97-99.	0.6	0
328	Burden Of Schizophrenia On Selected Comorbidities Costs. <i>Value in Health</i> , 2013, 16, A12.	0.1	0
329	Association study of Neuregulin-1 gene polymorphisms in a north Indian schizophrenia sample. <i>Schizophrenia Research</i> , 2013, 144, 24-30.	1.1	36
330	A population-based association study of 2q32.3 and 8q21.3 loci with schizophrenia in Han Chinese. <i>Journal of Psychiatric Research</i> , 2013, 47, 712-717.	1.5	43
331	Cognitive deficits and its relation with psychopathology and global functioning in first episode schizophrenia. <i>Asian Journal of Psychiatry</i> , 2013, 6, 537-543.	0.9	25
332	Has the prevalence, clinical presentation and social functioning of schizophrenia changed over the last 25years? Nithsdale schizophrenia survey revisited. <i>Schizophrenia Research</i> , 2013, 146, 349-356.	1.1	18

#	ARTICLE	IF	CITATIONS
333	Lifetime and 12-month prevalence rates of sub-clinical psychosis symptoms in a community cohort of 50-year-old individuals. <i>European Psychiatry</i> , 2013, 28, 302-307.	0.1	10
334	Polymorphisms in schizophrenia candidate gene UFD1L may contribute to cognitive deficits. <i>Psychiatry Research</i> , 2013, 209, 110-113.	1.7	5
335	Association of rs1344706 in the ZNF804A gene with schizophrenia in a case/control sample from Indonesia. <i>Schizophrenia Research</i> , 2013, 147, 46-52.	1.1	30
336	Discrimination between schizophrenia and major depressive disorder by magnetic resonance imaging of the female brain. <i>Journal of Psychiatric Research</i> , 2013, 47, 1383-1388.	1.5	27
337	Community pharmacy loyalty among individuals with schizophrenia. <i>Research in Social and Administrative Pharmacy</i> , 2013, 9, 806-816.	1.5	8
338	Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort. <i>Journal of Psychiatric Research</i> , 2013, 47, 1615-1622.	1.5	15
339	Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-7.	0.7	6
340	Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. <i>Psychological Medicine</i> , 2013, 43, 471-481.	2.7	860
341	Are the rates of schizophrenia unusually high in Canada? A comparison of Canadian and international data. <i>Psychiatry Research</i> , 2013, 209, 259-265.	1.7	11
342	Obstructive sleep apnoea and schizophrenia – A research agenda. <i>Sleep Medicine Reviews</i> , 2013, 17, 357-365.	3.8	42
343	Pharmacological and Psychosocial Management of Mental, Neurological and Substance Use Disorders in Low- and Middle-Income Countries: Issues and Current Strategies. <i>Drugs</i> , 2013, 73, 1549-1568.	4.9	13
344	Research Policies for Schizophrenia in the Global Health Context. <i>International Journal of Mental Health</i> , 2013, 42, 51-76.	0.5	1
345	Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. <i>Journal of Medical Economics</i> , 2013, 16, 1290-1299.	1.0	40
346	The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. <i>Epigenomics</i> , 2013, 5, 317-329.	1.0	26
347	Mental illness and psychiatric treatment amongst firesetters, other offenders and the general community. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 945-953.	1.3	22
348	The structure of psychopathology: Toward an expanded quantitative empirical model.. <i>Journal of Abnormal Psychology</i> , 2013, 122, 281-294.	2.0	274
349	Rorschach measures of cognition relate to everyday and social functioning in schizophrenia.. <i>Psychological Assessment</i> , 2013, 25, 253-263.	1.2	24
350	Risk factors for violence among forensic psychiatric inpatients. <i>Middle East Current Psychiatry</i> , 2013, 20, 1-5.	0.5	0

#	ARTICLE	IF	CITATIONS
351	Optimal Extent of Dopamine D2 Receptor Occupancy by Antipsychotics for Treatment of Dopamine Supersensitivity Psychosis and Late-Onset Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 398-404.	0.7	86
352	Evolutionary biology and anthropology suggest biome reconstitution as a necessary approach toward dealing with immune disorders. <i>Evolution, Medicine and Public Health</i> , 2013, 2013, 89-103.	1.1	63
353	Psychosis Following Traumatic Brain Injury. <i>Brain Impairment</i> , 2013, 14, 21-41.	0.5	28
354	Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia. <i>Epigenetics</i> , 2013, 8, 584-590.	1.3	55
355	A Novel Model of Schizophrenia Age-of-Onset Data Challenges the Conventional Interpretations of the Discordance in Monozygote Twin Studies. , 2013, 2013, 1-10.		1
356	Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive <i>Toxoplasma gondii</i> Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders. <i>Journal of Pathogens</i> , 2013, 2013, 1-29.	0.9	76
357	The Challenge of Adherence in Schizophrenia. , 2013, , .		0
358	Potential metabolite markers of schizophrenia. <i>Molecular Psychiatry</i> , 2013, 18, 67-78.	4.1	220
360	Epigenetics as the Underlying Mechanism for Monozygotic Twin Discordance. <i>Medical Epigenetics</i> , 2013, 1, 3-18.	262.3	6
364	Surgical Adverse Outcomes in Patients With Schizophrenia. <i>Annals of Surgery</i> , 2013, 257, 433-438.	2.1	90
366	The cost of schizophrenia in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 787.	1.0	47
367	The auditory steady-state response (ASSR). <i>Supplements To Clinical Neurophysiology</i> , 2013, 62, 101-112.	2.1	138
368	The genomics of schizophrenia: update and implications. <i>Journal of Clinical Investigation</i> , 2013, 123, 4557-4563.	3.9	87
369	Eye-Head Coordination Abnormalities in Schizophrenia. <i>PLoS ONE</i> , 2013, 8, e74845.	1.1	6
370	Trends and Significance of VRE Colonization in the ICU: A Meta-Analysis of Published Studies. <i>PLoS ONE</i> , 2013, 8, e75658.	1.1	80
371	Shifted Coupling of EEG Driving Frequencies and fMRI Resting State Networks in Schizophrenia Spectrum Disorders. <i>PLoS ONE</i> , 2013, 8, e76604.	1.1	29
372	The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. <i>PLoS ONE</i> , 2013, 8, e76635.	1.1	235
373	Global Epidemiology of Mental Disorders: What Are We Missing?. <i>PLoS ONE</i> , 2013, 8, e65514.	1.1	148

#	ARTICLE	IF	CITATIONS
374	Pharmacogenetics in schizophrenia: a review of clozapine studies. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 305-317.	0.9	21
375	Accounting for individual differences in human associative learning. <i>Frontiers in Psychology</i> , 2013, 4, 588.	1.1	11
376	Perinatal complications and schizophrenia: involvement of the immune system. <i>Frontiers in Neuroscience</i> , 2013, 7, 110.	1.4	27
377	Cognitive Remediation of Neurocognitive Deficits in Schizophrenia. , 2013, , 123-153.		2
378	The Burden Attributable to Mental and Substance Use Disorders as Risk Factors for Suicide: Findings from the Global Burden of Disease Study 2010. <i>PLoS ONE</i> , 2014, 9, e91936.	1.1	335
379	PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia. <i>PLoS ONE</i> , 2014, 9, e87686.	1.1	14
380	Exome Sequencing in 53 Sporadic Cases of Schizophrenia Identifies 18 Putative Candidate Genes. <i>PLoS ONE</i> , 2014, 9, e112745.	1.1	79
381	Developing an Estimate of Supported Housing Needs for Persons with Serious Mental Illnesses. <i>International Journal of Population Research</i> , 2014, 2014, 1-9.	0.7	0
382	The Utility of Electromagnetic Activity Measures in Obsessive Compulsive Disorder and Schizophrenia. , 0, , .		0
383	Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 384.	1.8	45
384	Evolutionary conservation in genes underlying human psychiatric disorders. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 283.	1.0	27
385	Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study. <i>Current Alzheimer Research</i> , 2014, 11, 681-693.	0.7	95
386	Female Specific Association between NNMT Gene and Schizophrenia in a Han Chinese population. <i>International Journal of Medical Sciences</i> , 2014, 11, 1234-1239.	1.1	13
387	Meta-analyses of Blood Homocysteine Levels for Gender and Genetic Association Studies of the MTHFR C677T Polymorphism in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 1154-1163.	2.3	88
388	Vagal Nerve Stimulation Reverses Aberrant Dopamine System Function in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia. <i>Journal of Neuroscience</i> , 2014, 34, 9261-9267.	1.7	49
389	Modelling the incidence and mortality of psychotic disorders: Data from the second Australian national survey of psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 352-359.	1.3	24
390	Prenatal maternal immune activation causes epigenetic differences in adolescent mouse brain. <i>Translational Psychiatry</i> , 2014, 4, e434-e434.	2.4	88
391	Prevalence of psychoses in Stockholm County – A population-based study using comprehensive healthcare registers. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 60-65.	0.7	14

#	ARTICLE	IF	CITATIONS
392	Clinical utility gene card for: 15q13.3 microdeletion syndrome. <i>European Journal of Human Genetics</i> , 2014, 22, 1338-1338.	1.4	10
394	Fecal Contamination of Drinking-Water in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001644.	3.9	401
395	Burden of schizophrenia on selected comorbidity costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 259-267.	0.7	16
396	The prevalence of schizophrenia in mainland China: evidence from epidemiological surveys. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 244-256.	2.2	112
397	Adding insult to injury: Childhood and adolescent risk factors for psychosis predict lower fractional anisotropy in the superior longitudinal fasciculus in healthy adults. <i>Psychiatry Research - Neuroimaging</i> , 2014, 224, 296-302.	0.9	23
398	Fifty years' development and future perspectives of psychiatric register research. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 87-98.	2.2	36
399	Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1258-1264.	1.4	17
400	Systematic review and meta-analysis of psychiatric disorder and the perpetration of partner violence. <i>Epidemiology and Psychiatric Sciences</i> , 2014, 23, 361-376.	1.8	60
401	Genetic Modifiers and Subtypes in Schizophrenia. <i>Current Behavioral Neuroscience Reports</i> , 2014, 1, 197-205.	0.6	1
402	Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. <i>BMC Psychiatry</i> , 2014, 14, 282.	1.1	19
403	Genetic variants of interleukin-10 gene promoter are associated with schizophrenia in Saudi patients: A case-control study. <i>North American Journal of Medical Sciences</i> , 2014, 6, 558.	1.7	12
404	Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. <i>Psychological Medicine</i> , 2014, 44, 2163-2176.	2.7	155
405	Risk of Adult Schizophrenia and Its Relationship to Childhood IQ in the 1958 British Birth Cohort. <i>Schizophrenia Bulletin</i> , 2014, 40, 143-151.	2.3	26
406	How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library. <i>Psychological Medicine</i> , 2014, 44, 3387-3405.	2.7	23
407	Sex and schizophrenia: a review of gender differences. <i>Psychosis</i> , 2014, 6, 61-69.	0.4	66
408	Associations between polymorphisms of LSAMP gene and schizophrenia. <i>Psychiatry Research</i> , 2014, 215, 797-798.	1.7	22
409	A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. <i>Journal of Psychiatric Research</i> , 2014, 54, 134-140.	1.5	75
410	The Effect of Serious Mental Illness on the Risk of Rehospitalization Among Patients With Diabetes. <i>Psychosomatics</i> , 2014, 55, 134-143.	2.5	58

#	ARTICLE	IF	CITATIONS
411	The adverse health effects of chronic cannabis use. <i>Drug Testing and Analysis</i> , 2014, 6, 39-45.	1.6	288
412	The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 169-182.	1.6	68
413	Money matters: does the reimbursement policy for second-generation antipsychotics influence the number of recorded schizophrenia patients and the burden of stigmatization?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 531-539.	1.6	2
414	The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis. <i>Biological Psychiatry</i> , 2014, 75, 300-306.	0.7	161
415	6R-l-erythro-5,6,7,8-tetrahydrobiopterin (BH4): A potential treatment for all symptom domains of schizophrenia. <i>Medical Hypotheses</i> , 2014, 82, 395-397.	0.8	6
416	Synthesis, docking and pharmacological evaluation of novel indole based potential atypical antipsychotics. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 477-490.	2.6	12
417	Activation of the Maternal Immune System During Pregnancy Alters Behavioral Development of Rhesus Monkey Offspring. <i>Biological Psychiatry</i> , 2014, 75, 332-341.	0.7	249
418	Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. , 2014, 144, 50-59.		54
419	A Genetically Informed, Group fMRI Connectivity Modeling Approach: Application to Schizophrenia. <i>IEEE Transactions on Biomedical Engineering</i> , 2014, 61, 946-956.	2.5	12
420	The neurobiology of social environmental risk for schizophrenia: an evolving research field. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 507-517.	1.6	72
421	Cortical Inhibition, Excitation, and Connectivity in Schizophrenia: A Review of Insights From Transcranial Magnetic Stimulation. <i>Schizophrenia Bulletin</i> , 2014, 40, 685-696.	2.3	63
422	Risk of schizophrenia and minority status: A comparison of the Swedish-speaking minority and the Finnish-speaking majority in Finland. <i>Schizophrenia Research</i> , 2014, 159, 303-308.	1.1	15
423	New therapeutic approaches for treatment-resistant schizophrenia: A look to the future. <i>Journal of Psychiatric Research</i> , 2014, 58, 1-6.	1.5	57
424	Serum Vitamin D Levels in Relation to Schizophrenia: A Systematic Review and Meta-Analysis of Observational Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3863-3872.	1.8	102
425	Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice. <i>Genome Medicine</i> , 2014, 6, 29.	3.6	189
426	Estimating the population attributable fraction for schizophrenia when <i>Toxoplasma gondii</i> is assumed absent in human populations. <i>Preventive Veterinary Medicine</i> , 2014, 117, 425-435.	0.7	9
427	MRSA Colonization and Risk of Infection in the Neonatal and Pediatric ICU: A Meta-analysis. <i>Pediatrics</i> , 2014, 133, e1015-e1023.	1.0	96
428	Copy number variation in schizophrenia in Sweden. <i>Molecular Psychiatry</i> , 2014, 19, 762-773.	4.1	257

#	ARTICLE	IF	CITATIONS
429	Trifluoperazine versus placebo for schizophrenia. The Cochrane Library, 2014, , CD010226.	1.5	12
430	The urban risk and migration risk factors for schizophrenia: Are cats the answer?. Schizophrenia Research, 2014, 159, 299-302.	1.1	18
431	Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Molecular Psychiatry, 2014, 19, 1017-1024.	4.1	333
432	Insights from Proteomic Studies on Schizophrenia Preclinical Models: What Can We Learn for Drug Discovery?. Advances in Biological Psychiatry, 2014, , 56-73.	0.2	1
433	GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells. Molecular BioSystems, 2014, 10, 2398-2406.	2.9	61
434	No association of SLC6A3 and SLC6A4 gene polymorphisms with schizophrenia in the Han Chinese population. Neuroscience Letters, 2014, 579, 114-118.	1.0	7
435	Illness management and recovery programme for people with severe mental illness. The Cochrane Library, 2014, , .	1.5	2
436	The Cost-Effectiveness of Psychotherapy for the Major Psychiatric Diagnoses. Psychodynamic Psychiatry, 2014, 42, 423-457.	0.1	30
437	Systematic Prioritization and Integrative Analysis of Copy Number Variations in Schizophrenia Reveal Key Schizophrenia Susceptibility Genes. Schizophrenia Bulletin, 2014, 40, 1285-1299.	2.3	41
438	Exposure to stressful life events during pregnancy predicts psychotic experiences via behaviour problems in childhood. Journal of Psychiatric Research, 2014, 59, 132-139.	1.5	14
439	The contribution of genetic variants to disease depends on the ruler. Nature Reviews Genetics, 2014, 15, 765-776.	7.7	153
440	Effects of antipsychotic drugs on insight in schizophrenia. Psychiatry Research, 2014, 218, 20-24.	1.7	13
441	Perineuronal nets and schizophrenia: The importance of neuronal coatings. Neuroscience and Biobehavioral Reviews, 2014, 45, 85-99.	2.9	79
442	The synapse in schizophrenia. European Journal of Neuroscience, 2014, 39, 1059-1067.	1.2	53
443	Excess Early Mortality in Schizophrenia. Annual Review of Clinical Psychology, 2014, 10, 425-448.	6.3	602
444	Schizophrenia: Blood-Serum-Plasma Metabolomics. Advances in Biological Psychiatry, 2014, , 27-27.	0.2	0
445	Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry,the, 2014, 1, 44-54.	3.7	228
446	Discovery of the First Potent and Orally Available Agonist of the Orphan G-Protein-Coupled Receptor 52. Journal of Medicinal Chemistry, 2014, 57, 5226-5237.	2.9	38

#	ARTICLE	IF	CITATIONS
447	Alterations in dopamine system function across the estrous cycle of the MAM rodent model of schizophrenia. <i>Psychoneuroendocrinology</i> , 2014, 47, 88-97.	1.3	31
448	Association between cannabis use and schizotypal dimensions – A meta-analysis of cross-sectional studies. <i>Psychiatry Research</i> , 2014, 219, 58-66.	1.7	42
449	Prevalence of schizophrenia disability and associated mortality among Chinese men and women. <i>Psychiatry Research</i> , 2014, 220, 181-187.	1.7	33
451	Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. <i>Journal of Neuroimmunology</i> , 2014, 269, 68-75.	1.1	19
452	Further evidence for genetic association of CACNA1C and schizophrenia: New risk loci in a Han Chinese population and a meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 105-110.	1.1	35
453	Effects of the nicotinic $\alpha 7$ receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats. <i>Psychopharmacology</i> , 2014, 231, 3695-3706.	1.5	36
454	A Matrilineal Genetic Legacy from the Last Glacial Maximum Confers Susceptibility to Schizophrenia in Han Chinese. <i>Journal of Genetics and Genomics</i> , 2014, 41, 397-407.	1.7	28
455	Presynaptic Dopaminergic Function: Implications for Understanding Treatment Response in Psychosis. <i>CNS Drugs</i> , 2014, 28, 649-663.	2.7	5
456	A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. <i>Schizophrenia Research</i> , 2014, 157, 238-243.	1.1	53
457	Neuroimaging Biomarkers for Early Drug Development in Schizophrenia. <i>Biological Psychiatry</i> , 2014, 76, 111-119.	0.7	48
459	Intervention précoce pour la psychose: concepts, connaissances actuelles et orientations futures. <i>Sante Mentale Au Quebec</i> , 0, 39, 201-229.	0.1	12
460	Synthesis and <i>in Vivo</i> Evaluation of Novel Quinoline Derivatives as Phosphodiesterase 10A Inhibitors. <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 1200-1213.	0.6	11
461	Horticultural therapy for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD009413.	1.5	10
462	Influence of NRG1 rs12807809 polymorphism on symptom severity in individuals with schizophrenia in the Han population but not the Zhuang population of south China. <i>Acta Neuropsychiatrica</i> , 2015, 27, 221-227.	1.0	11
463	The relationship between schizophrenia and rheumatoid arthritis revisited: Genetic and epidemiological analyses. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 81-88.	1.1	29
464	Decreased bilateral thalamic gray matter volume in first-episode schizophrenia with prominent hallucinatory symptoms: A volumetric MRI study. <i>Scientific Reports</i> , 2015, 5, 14505.	1.6	42
465	Serum trace element differences between Schizophrenia patients and controls in the Han Chinese population. <i>Scientific Reports</i> , 2015, 5, 15013.	1.6	46
468	The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. <i>PLoS ONE</i> , 2015, 10, e0116820.	1.1	908

#	ARTICLE	IF	CITATIONS
469	A Surveillance System to Monitor Excess Mortality of People with Mental Illness in Canada. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 571-579.	0.9	56
471	Feasibility and acceptability of patient partnership to improve access to primary care for the physical health of patients with severe mental illnesses: an interactive guide. <i>International Journal for Equity in Health</i> , 2015, 14, 78.	1.5	23
472	Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study. <i>Journal of Translational Medicine</i> , 2015, 13, 226.	1.8	50
473	Avatar therapy for schizophrenia or related disorders. <i>The Cochrane Library</i> , 0, , .	1.5	5
474	Overview of genetic research in anorexia nervosa: The past, the present and the future. <i>International Journal of Eating Disorders</i> , 2015, 48, 814-825.	2.1	20
475	Does the quality and outcomes framework reduce psychiatric admissions in people with serious mental illness? A regression analysis. <i>BMJ Open</i> , 2015, 5, e007342-e007342.	0.8	15
476	Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. <i>BJPsych Open</i> , 2015, 1, 67-73.	0.3	12
477	Multiply disadvantaged: Health and service utilisation factors faced by homeless injecting drug consumers in Australia. <i>Drug and Alcohol Review</i> , 2015, 34, 379-387.	1.1	42
478	Asenapine versus placebo for schizophrenia. <i>The Cochrane Library</i> , 2015, , CD011458.	1.5	7
479	Cocaine Use in Individuals With Schizophrenia. <i>Journal of Addiction Medicine</i> , 2015, 9, 177-180.	1.4	2
480	Childhood neglect predicts disorganization in schizophrenia through grey matter decrease in dorsolateral prefrontal cortex. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 244-256.	2.2	40
481	Neural Network Reorganization Analysis During an Auditory Oddball Task in Schizophrenia Using Wavelet Entropy. <i>Entropy</i> , 2015, 17, 5241-5256.	1.1	34
482	Use of concomitant medication in the treatment of schizophrenia. <i>African Journal of Pharmacy and Pharmacology</i> , 2015, 9, 609-614.	0.2	0
483	Productivity loss and resource utilization, and associated indirect and direct costs in individuals providing care for adults with schizophrenia in the EU5. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 593.	0.7	22
484	Basic research Apolipoprotein E polymorphism is associated with susceptibility to schizophrenia among Saudis. <i>Archives of Medical Science</i> , 2015, 4, 869-876.	0.4	16
485	Lack of Association between the TSPAN18 Gene and Schizophrenia Based on New Data from Han Chinese and a Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2015, 16, 11864-11872.	1.8	10
486	Targeting Glia with N-Acetylcysteine Modulates Brain Glutamate and Behaviors Relevant to Neurodevelopmental Disorders in C57BL/6J Mice. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 343.	1.0	32
487	Association of Histamine N-Methyltransferase Thr105Ile Polymorphism with Parkinson's Disease and Schizophrenia in Han Chinese: A Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0119692.	1.1	19

#	ARTICLE	IF	CITATIONS
488	Gender Differences in Individuals at High-Risk of Psychosis: A Comprehensive Literature Review. <i>Scientific World Journal</i> , The, 2015, 2015, 1-13.	0.8	88
490	Evidence of a sex-dependent restrictive epigenome in schizophrenia. <i>Journal of Psychiatric Research</i> , 2015, 65, 87-94.	1.5	32
491	Recent Positive Selection Drives the Expansion of a Schizophrenia Risk Nonsynonymous Variant at <i>SLC39A8</i> in Europeans. <i>Schizophrenia Bulletin</i> , 2016, 42, sbv070.	2.3	35
492	Cost-Effectiveness of School-Based Prevention of Cannabis Use. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 525-542.	1.0	12
493	Abnormal immune system development and function in schizophrenia helps reconcile diverse findings and suggests new treatment and prevention strategies. <i>Brain Research</i> , 2015, 1617, 93-112.	1.1	17
494	Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. <i>Schizophrenia Research</i> , 2015, 167, 57-63.	1.1	29
495	Improving risk assessment in schizophrenia: epidemiological investigation of criminal history factors. <i>British Journal of Psychiatry</i> , 2015, 206, 424-430.	1.7	23
496	Differences in parental bonding between schizophrenia and bipolar disorder: Evidence of prodromal symptoms?. <i>Schizophrenia Research</i> , 2015, 165, 134-137.	1.1	7
497	Psychotic Experiences in the General Population. <i>JAMA Psychiatry</i> , 2015, 72, 697.	6.0	387
498	Genetic variants in long non-coding RNA MIAT contribute to risk of paranoid schizophrenia in a Chinese Han population. <i>Schizophrenia Research</i> , 2015, 166, 125-130.	1.1	62
499	Machine Cognition and the Integration of Emotional Response in the Monitoring of Mental Disorders. , 2015, , .		1
500	Urbanization and the prevalence of schizophrenia in China between 1990 and 2010. <i>World Psychiatry</i> , 2015, 14, 251-252.	4.8	37
501	An evaluation of variation in published estimates of schizophrenia prevalence from 1990 to 2013: a systematic literature review. <i>BMC Psychiatry</i> , 2015, 15, 193.	1.1	228
502	Relationships Between Perceived Stigma, Coping Orientations, Self-esteem, and Quality of Life in Patients With Schizophrenia. <i>Asia-Pacific Journal of Public Health</i> , 2015, 27, NP1932-NP1941.	0.4	36
503	Role functioning among adults with schizophrenia. <i>British Journal of Occupational Therapy</i> , 2015, 78, 158-165.	0.5	5
504	Knowledge in schizophrenia: The Portuguese version of KAST (Knowledge About Schizophrenia Test) and analysis of social-demographic and clinical factors' influence. <i>Schizophrenia Research</i> , 2015, 168, 168-173.	1.1	5
505	Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 570-574.	0.8	79
506	Comorbid substance use disorders in schizophrenia: A latent class approach. <i>Psychiatry Research</i> , 2015, 225, 395-401.	1.7	24

#	ARTICLE	IF	CITATIONS
508	Striatal shape abnormalities as novel neurodevelopmental endophenotypes in schizophrenia: A longitudinal study. <i>Human Brain Mapping</i> , 2015, 36, 1458-1469.	1.9	65
509	Altered microRNA Expression in Peripheral Blood Mononuclear Cells from Young Patients with Schizophrenia. <i>Journal of Molecular Neuroscience</i> , 2015, 56, 562-571.	1.1	35
510	Treatment of clozapine-associated weight gain: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 389-401.	0.8	40
511	Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. <i>Schizophrenia Research</i> , 2015, 162, 169-174.	1.1	26
512	A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 51, 15-30.	2.9	119
513	Mitochondrial dysfunction in schizophrenia: an evolutionary perspective. <i>Human Genetics</i> , 2015, 134, 13-21.	1.8	28
514	Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT). <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 318-323.	1.3	32
515	Glutamate and dopamine in schizophrenia: An update for the 21 st century. <i>Journal of Psychopharmacology</i> , 2015, 29, 97-115.	2.0	596
516	Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 378-389.	0.5	41
517	Use of GP services by patients with schizophrenia: a national cross-sectional register-based study. <i>BMC Health Services Research</i> , 2015, 15, 66.	0.9	19
518	Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. <i>Biomarker Research</i> , 2015, 3, 3.	2.8	15
519	Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 579-592.	0.6	25
520	Examining endogenous dopamine in treated schizophrenia using [11C]-(+)-PHNO positron emission tomography: A pilot study. <i>Clinica Chimica Acta</i> , 2015, 449, 60-62.	0.5	29
521	A2BP1 gene polymorphisms association with olanzapine-induced weight gain. <i>Pharmacological Research</i> , 2015, 99, 155-161.	3.1	7
522	LPA signaling initiates schizophrenia-like brain and behavioral changes in a mouse model of prenatal brain hemorrhage. <i>Translational Psychiatry</i> , 2015, 5, e541-e541.	2.4	40
523	Why searching for psychosis in diverse settings is important for global research and mental health systems development. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 895-897.	1.6	8
524	Rate and predictors of psychotic symptoms after Kashmir earthquake. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 471-481.	1.8	11
525	Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. <i>CNS Spectrums</i> , 2015, 20, 140-147.	0.7	28

#	ARTICLE	IF	CITATIONS
526	Psychoeducation for siblings of people with severe mental illness. The Cochrane Library, 2015, 2015, CD010540.	1.5	18
527	Addressing phototoxicity observed in a novel series of biaryl derivatives: Discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436. Bioorganic and Medicinal Chemistry, 2015, 23, 3351-3367.	1.4	8
528	Hospital Length of Stay in Individuals With Schizophrenia With and Without Cocaine-Positive Urine Drug Screens at Hospital Admission. Journal of Nervous and Mental Disease, 2015, 203, 33-36.	0.5	5
529	Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders. , 2015, , 233-271.		3
530	Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Medical Hypotheses, 2015, 85, 391-396.	0.8	11
531	A systematic review of mental disorders and perpetration of domestic violence among military populations. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 1329-1346.	1.6	40
532	Prevalence of psychotic disorders in an urban area of France. BMC Psychiatry, 2015, 15, 204.	1.1	14
533	Association study of GRM7 polymorphisms and schizophrenia in the Chinese Han population. Neuroscience Letters, 2015, 604, 109-112.	1.0	8
534	Immigration and psychotic experiences in the United States: Another example of the epidemiological paradox?. Psychiatry Research, 2015, 229, 784-790.	1.7	23
535	Associations between psychotic symptoms and substance use in young offenders. Drug and Alcohol Review, 2015, 34, 673-682.	1.1	21
536	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology, 2015, 44, 1706-1721.	0.9	53
537	Simulation in Nursing Education: iPod As a Teaching Tool for Undergraduate Nurses. Issues in Mental Health Nursing, 2015, 36, 505-512.	0.6	7
538	The interactive effects of type 2 diabetes mellitus and schizophrenia on all-cause mortality: The Fremantle Diabetes Study. Journal of Diabetes and Its Complications, 2015, 29, 1320-1322.	1.2	5
539	Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition. Bioorganic and Medicinal Chemistry, 2015, 23, 297-313.	1.4	21
540	Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. Neuroscience and Biobehavioral Reviews, 2015, 48, 10-21.	2.9	214
541	What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?. Addiction, 2015, 110, 19-35.	1.7	440
542	Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis. Journal of Neural Transmission, 2015, 122, 307-320.	1.4	30
543	Liver Illness and Psychiatric Patients. Hepatitis Monthly, 2016, 16, e41564.	0.1	19

#	ARTICLE	IF	CITATIONS
544	Schizophrenia and Suicide Attempts: Findings from a Representative Community-Based Canadian Sample. <i>Schizophrenia Research and Treatment</i> , 2016, 2016, 1-11.	0.7	36
545	Global economic burden of schizophrenia: a systematic review. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 357.	1.0	351
546	The Influence of Diet and the Gut Microbiota in Schizophrenia. , 2016, , 339-362.		1
547	Editorial: Schizophrenia: Human and Animal Studies. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 76.	1.0	2
548	Foreign Accent Syndrome As a Psychogenic Disorder: A Review. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 168.	1.0	15
549	From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism. <i>Frontiers in Neuroscience</i> , 2016, 10, 488.	1.4	30
550	Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2016, 15, 174-183.	1.4	63
552	Modeling Gene-Environment Interaction in Schizophrenia. <i>Handbook of Behavioral Neuroscience</i> , 2016, 23, 345-360.	0.7	2
553	Trauma Exposure, Schizophrenia Symptoms, and the Stress Vulnerability Model. , 2016, , 205-229.		4
554	Further evidence of <i>VRK2</i> rs2312147 associated with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 457-466.	1.3	15
555	Health status and use of medications by adults with intellectual disability in Western Australia. <i>Journal of Intellectual and Developmental Disability</i> , 2016, 41, 87-96.	1.1	14
556	The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 192-201.	0.9	46
557	GWAS-identified schizophrenia risk SNPs at <i>TSPAN18</i> are highly diverged between Europeans and East Asians. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 1032-1040.	1.1	9
558	Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. <i>Drug Development Research</i> , 2016, 77, 53-72.	1.4	30
559	Prevalence of nonaffective psychosis in intellectually disabled clients. <i>Psychiatric Genetics</i> , 2016, 26, 145-155.	0.6	16
560	Asenapine: A Review in Schizophrenia. <i>CNS Drugs</i> , 2016, 30, 655-666.	2.7	19
561	Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. <i>Folia Medica</i> , 2016, 58, 12-18.	0.2	11
562	Involvement of the histamine H4 receptor in clozapine-induced hematopoietic toxicity: Vulnerability under granulocytic differentiation of HL-60 cells. <i>Toxicology and Applied Pharmacology</i> , 2016, 306, 8-16.	1.3	15

#	ARTICLE	IF	CITATIONS
563	Analysis of the non-stationarity of neural activity during an auditory oddball task in schizophrenia. , 2016, 2016, 3724-3727.		1
564	Spatial distribution of psychotic disorders in an urban area of France: an ecological study. Scientific Reports, 2016, 6, 26190.	1.6	8
565	Database methodology for therapy evaluation in auditory schizophrenia disorder based on continuity evolution of symptoms. , 2016, , .		5
566	Emotional simulations and depression diagnostics. Biologically Inspired Cognitive Architectures, 2016, 18, 41-50.	0.9	4
567	Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research, 2016, 174, 93-98.	1.1	49
568	Synthesis and optimization of N -heterocyclic pyridinones as catechol- O -methyltransferase (COMT) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2952-2956.	1.0	8
569	The Prevalence of Electroconvulsive Therapy Use Since 1973. Journal of ECT, 2016, 32, 236-242.	0.3	34
570	Pro-inflammatory cytokines and their epistatic interactions in genetic susceptibility to schizophrenia. Journal of Neuroinflammation, 2016, 13, 105.	3.1	46
571	The association between childhood relocations and subsequent risk of suicide attempt, psychiatric problems, and low academic achievement. Psychological Medicine, 2016, 46, 969-979.	2.7	10
572	A systematic examination of the nature and content of vignettes in schizophrenia research. Journal of Mental Health, 2016, 25, 189-196.	1.0	4
573	Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records. Nordic Journal of Psychiatry, 2016, 70, 450-455.	0.7	20
574	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 2016, 50, 410-472.	1.3	571
575	Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders. Psychiatry Research, 2016, 245, 427-435.	1.7	9
576	Suicidality in body dysmorphic disorder (BDD): A systematic review with meta-analysis. Clinical Psychology Review, 2016, 49, 55-66.	6.0	116
577	Common variants in the chromosome 2p23 region containing the SLC30A3 (ZnT3) gene are associated with schizophrenia in female but not male individuals in a large collection of European samples. Psychiatry Research, 2016, 246, 335-340.	1.7	21
578	Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. Experimental Neurology, 2016, 286, 32-39.	2.0	25
579	Effects of varenicline on motor cortical plasticity in non-smokers with schizophrenia. Schizophrenia Research, 2016, 178, 50-55.	1.1	2
580	A preliminary analysis of microRNA-21 expression alteration after antipsychotic treatment in patients with schizophrenia. Psychiatry Research, 2016, 244, 324-332.	1.7	27

#	ARTICLE	IF	CITATIONS
582	Body dysmorphic disorder in different settings: A systematic review and estimated weighted prevalence. <i>Body Image</i> , 2016, 18, 168-186.	1.9	244
583	The dopamine beta-hydroxylase gene polymorphism rs1611114 is associated with schizophrenia in the Chinese Zhuang but not Chinese Han population. <i>Molecular Genetics and Genomics</i> , 2016, 291, 1813-1821.	1.0	4
584	Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. <i>Microbial Biotechnology</i> , 2016, 10, 365-377.	0.9	71
585	Characterizing psychosis risk traits in Africa: A longitudinal study of Kenyan adolescents. <i>Schizophrenia Research</i> , 2016, 176, 340-348.	1.1	29
586	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2016, 2016, CD010832.	1.5	4
587	The impact of IL10 polymorphisms and sHLA-G levels on the risk of schizophrenia. <i>Asian Journal of Psychiatry</i> , 2016, 23, 39-43.	0.9	10
589	A study of type-1 diabetes associated autoantibodies in schizophrenia. <i>Schizophrenia Research</i> , 2016, 176, 186-190.	1.1	16
591	Triggers for Violent Criminality in Patients With Psychotic Disorders. <i>JAMA Psychiatry</i> , 2016, 73, 796.	6.0	69
592	SZDB: A Database for Schizophrenia Genetic Research. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw102.	2.3	91
593	Risk Overlap Between Clinical Disorders. , 2016, , 387-396.		0
594	Effectiveness of group body psychotherapy for negative symptoms of schizophrenia: Multicentre randomised controlled trial. <i>British Journal of Psychiatry</i> , 2016, 209, 54-61.	1.7	47
595	A significant causal association between C-reactive protein levels and schizophrenia. <i>Scientific Reports</i> , 2016, 6, 26105.	1.6	40
596	A systematic review of the prevalence and odds of domestic abuse victimization among people with dementia. <i>International Review of Psychiatry</i> , 2016, 28, 475-484.	1.4	25
597	Cumulative effect of the plasma total homocysteine-related genetic variants on schizophrenia risk. <i>Psychiatry Research</i> , 2016, 246, 833-837.	1.7	14
598	An Integrated Model?. <i>Cultural Studies of Science and Medicine</i> , 2016, , 131-177.	0.7	3
599	Screening of mental disorders in workplace. <i>Health Evaluation and Promotion</i> , 2016, 43, 313-319.	0.0	0
600	Women and schizophrenia. , 0, , 294-306.		13
601	Risk and functional significance of psychotic experiences among individuals with depression in 44 low- and middle-income countries. <i>Psychological Medicine</i> , 2016, 46, 2655-2665.	2.7	45

#	ARTICLE	IF	CITATIONS
602	Experiences of medication adherence among people with schizophrenia. JBI Database of Systematic Reviews and Implementation Reports, 2016, 14, 51-57.	1.7	0
603	Reliability, validity and factorial structure of the Arabic version of the international suicide prevention trial (InterSePT) scale for suicidal thinking in schizophrenia patients in Doha, Qatar. BMC Psychiatry, 2016, 16, 437.	1.1	6
604	Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. The Cochrane Library, 2016, 2016, CD010631.	1.5	23
605	Chlorpromazine versus reserpine for schizophrenia. The Cochrane Library, 2016, 4, CD012122.	1.5	11
606	Employment and income among first-time cases diagnosed with non-affective psychosis in Stockholm, Sweden: a follow-up study 2004/2005-2010. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 259-267.	1.6	7
607	Brief Interventions for Psychosis. , 2016, , .		6
608	Association of Genetic Risk for Schizophrenia With Nonparticipation Over Time in a Population-Based Cohort Study. American Journal of Epidemiology, 2016, 183, 1149-1158.	1.6	118
609	Progress and Future Directions in Research on the Psychosis Prodrome. Harvard Review of Psychiatry, 2016, 24, 87-103.	0.9	55
610	Exploring Differences between Successful and Unsuccessful Mental Disorder Defences. Canadian Journal of Criminology and Criminal Justice, 2016, 58, 161-193.	0.3	1
611	High estrogen and chronic haloperidol lead to greater amphetamine-induced BOLD activation in awake, amphetamine-sensitized female rats. Hormones and Behavior, 2016, 82, 56-63.	1.0	14
612	Do people with bipolar disorders have access to psychosocial treatments? A survey in Italy. International Journal of Social Psychiatry, 2016, 62, 334-344.	1.6	22
613	Amygdala volume is reduced in early course schizophrenia. Psychiatry Research - Neuroimaging, 2016, 250, 50-60.	0.9	33
614	The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia. Molecular and Cellular Therapies, 2016, 4, 2.	0.2	51
615	Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs. Human Psychopharmacology, 2016, 31, 113-120.	0.7	5
616	Prevalence of schizophrenia and related disorders in Malaga (Spain): results using multiple clinical databases. Epidemiology and Psychiatric Sciences, 2016, 25, 38-48.	1.8	18
617	nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. Schizophrenia Research, 2016, 171, 1-15.	1.1	71
619	Olanzapine pamoate for the treatment of schizophrenia - a safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 403-411.	1.0	5
620	Genetic association of GWAS-supported MAD1L1 gene polymorphism rs12666575 with schizophrenia susceptibility in a Chinese population. Neuroscience Letters, 2016, 610, 98-103.	1.0	17

#	ARTICLE	IF	CITATIONS
621	Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons. <i>Molecular and Cellular Neurosciences</i> , 2016, 73, 52-62.	1.0	66
622	The Historical, Cultural, Epistemological and Research Context of Remitting-Relapsing Psychosis in Timor-Leste. <i>Cultural Studies of Science and Medicine</i> , 2016, , 1-50.	0.7	0
623	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. <i>Lancet Neurology</i> , The, 2016, 15, 585-596.	4.9	77
624	Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2016, 171, 215-224.	1.1	130
625	No association between ZNF804A rs1344706 and schizophrenia in a case-control study of Han Chinese. <i>Neuroscience Letters</i> , 2016, 618, 14-18.	1.0	12
626	Sex/gender differences in the brain and cognition in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 67, 57-78.	2.9	195
627	Family caregivers and outcome of people with schizophrenia in rural China: 14-year follow-up study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2016, 51, 513-520.	1.6	49
628	Predicting spectrums of adult mania, psychosis and depression by prospectively ascertained childhood neurodevelopment. <i>Journal of Psychiatric Research</i> , 2016, 72, 22-29.	1.5	21
629	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. <i>Biological Psychiatry</i> , 2016, 80, e19-e20.	0.7	4
630	Animal models of gene-environment interaction in schizophrenia: A dimensional perspective. <i>Progress in Neurobiology</i> , 2016, 136, 1-27.	2.8	67
631	Psychosis in Machado-Joseph Disease: Clinical Correlates, Pathophysiological Discussion, and Functional Brain Imaging. Expanding the Cerebellar Cognitive Affective Syndrome. <i>Cerebellum</i> , 2016, 15, 483-490.	1.4	13
632	Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers. <i>Schizophrenia Bulletin</i> , 2016, 42, 476-483.	2.3	121
633	Pathophysiological Role of HERV-W in Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, 17-25.	0.9	15
634	What does the broken brain say to the neuroscientist? Oscillations and connectivity in schizophrenia, Alzheimer's disease, and bipolar disorder. <i>International Journal of Psychophysiology</i> , 2016, 103, 135-148.	0.5	59
635	Evaluation of European Schizophrenia GWAS Loci in Asian Populations via Comprehensive Meta-Analyses. <i>Molecular Neurobiology</i> , 2017, 54, 4071-4080.	1.9	19
636	Unique and Overlapping Symptoms in Schizophrenia Spectrum and Dissociative Disorders in Relation to Models of Psychopathology: A Systematic Review. <i>Schizophrenia Bulletin</i> , 2017, 43, 108-121.	2.3	89
637	Murder and psychosis: Neuropsychological profiles of homicide offenders with schizophrenia. <i>Criminal Behaviour and Mental Health</i> , 2017, 27, 146-161.	0.4	20
638	The MATCH cohort study in the Netherlands: rationale, objectives, methods and baseline characteristics of patients with (long-term) common mental disorders. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	1.1	7

#	ARTICLE	IF	CITATIONS
639	Associations between neurodevelopmental genes, neuroanatomy, and ultra high risk symptoms of psychosis in 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 295-314.	1.1	25
640	Common developmental genome deprogramming in schizophrenia – Role of Integrative Nuclear FGFR1 Signaling (INFS). <i>Schizophrenia Research</i> , 2017, 185, 17-32.	1.1	57
641	Variability of 128 schizophrenia-associated gene variants across distinct ethnic populations. <i>Translational Psychiatry</i> , 2017, 7, e988-e988.	2.4	22
642	Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness. <i>The Cochrane Library</i> , 2017, 2017, CD011464.	1.5	37
643	No evidence for the presence of genetic variants predisposing to psychotic disorders on the non-deleted 22q11.2 allele of VCFS patients. <i>Translational Psychiatry</i> , 2017, 7, e1039-e1039.	2.4	9
644	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 82-90.	1.2	61
645	Longitudinal study of premorbid adjustment in 22q11.2 deletion (velocardiofacial) syndrome and association with psychosis. <i>Development and Psychopathology</i> , 2017, 29, 93-106.	1.4	11
646	Functional near infra-red spectroscopy (fNIRS) in schizophrenia: A review. <i>Asian Journal of Psychiatry</i> , 2017, 27, 18-31.	0.9	44
647	The impact of clozapine on hospital use: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 296-309.	2.2	90
648	Feasibility and acceptability of post-hospitalization ecological momentary assessment in patients with psychotic-spectrum disorders. <i>Comprehensive Psychiatry</i> , 2017, 74, 204-213.	1.5	34
649	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 235-248.	0.9	19
650	Social isolation induces schizophrenia-like behavior potentially associated with HINT1, NMDA receptor, and dopamine receptor 2. <i>NeuroReport</i> , 2017, 28, 462-469.	0.6	31
651	Comparative study on serum levels of macro and trace elements in schizophrenia based on supervised learning methods. <i>Journal of Trace Elements in Medicine and Biology</i> , 2017, 43, 202-208.	1.5	15
652	Small non-coding RNA expression from anterior cingulate cortex in schizophrenia shows sex specific regulation. <i>Schizophrenia Research</i> , 2017, 183, 82-87.	1.1	17
653	Identification of low risk of violent crime in severe mental illness with a clinical prediction tool (Oxford Mental Illness and Violence tool [OxMIV]): a derivation and validation study. <i>Lancet Psychiatry</i> , 2017, 4, 461-468.	3.7	49
654	Exploring non-stationarity patterns in schizophrenia: neural reorganization abnormalities in the alpha band. <i>Journal of Neural Engineering</i> , 2017, 14, 046001.	1.8	29
655	Motor system dysfunction in the schizophrenia diathesis: Neural systems to neurotransmitters. <i>European Psychiatry</i> , 2017, 44, 125-133.	0.1	39
656	Risk of psychosis in refugees: a literature review. <i>Translational Psychiatry</i> , 2017, 7, e1149-e1149.	2.4	43

#	ARTICLE	IF	CITATIONS
657	Validation of the Five-Factor Model of the Arabic Version of the Positive and Negative Syndrome Scale in Schizophrenia. <i>Psychopathology</i> , 2017, 50, 211-218.	1.1	7
658	Catechol-O-methyltransferase gene promoter methylation as a peripheral biomarker in male schizophrenia. <i>European Psychiatry</i> , 2017, 44, 39-46.	0.1	27
659	An emerging role for mitochondrial dynamics in schizophrenia. <i>Schizophrenia Research</i> , 2017, 187, 26-32.	1.1	60
660	Lifetime Prevalence and Correlates of Schizophrenia-Spectrum, Affective, and Other Non-affective Psychotic Disorders in the Chinese Adult Population. <i>Schizophrenia Bulletin</i> , 2017, 43, 1280-1290.	2.3	55
661	Whole-genome sequencing of monozygotic twins discordant for schizophrenia indicates multiple genetic risk factors for schizophrenia. <i>Journal of Genetics and Genomics</i> , 2017, 44, 295-306.	1.7	36
662	Recent life events and psychosis: The role of childhood adversities. <i>Psychiatry Research</i> , 2017, 256, 111-117.	1.7	31
663	Clozapine dose for schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD009555.	1.5	33
664	A population-level metric for gambling-related harm. <i>International Gambling Studies</i> , 2017, 17, 163-175.	1.3	73
665	Caveolin-1 regulation of <i>disrupted-in-schizophrenia-1</i> as a potential therapeutic target for schizophrenia. <i>Journal of Neurophysiology</i> , 2017, 117, 436-444.	0.9	27
666	Replicated association between the European GWAS locus rs10503253 at CSMD1 and schizophrenia in Asian population. <i>Neuroscience Letters</i> , 2017, 647, 122-128.	1.0	17
667	Association among serum cortisol, dehydroepiandrosterone-sulfate levels and psychiatric symptoms in men with chronic schizophrenia. <i>Comprehensive Psychiatry</i> , 2017, 76, 113-118.	1.5	10
668	The schizophrenia risk gene ZNF804A: clinical associations, biological mechanisms and neuronal functions. <i>Molecular Psychiatry</i> , 2017, 22, 944-953.	4.1	59
669	Disruptions in the left frontoparietal network underlie resting state endophenotypic markers in schizophrenia. <i>Human Brain Mapping</i> , 2017, 38, 1741-1750.	1.9	40
670	Correlates of vitamin D in psychotic disorders: A comprehensive systematic review. <i>Psychiatry Research</i> , 2017, 249, 78-85.	1.7	34
671	Analysis of differential gene expression mediated by clozapine in human postmortem brains. <i>Schizophrenia Research</i> , 2017, 185, 58-66.	1.1	14
673	Clinical characteristics of breast cancer patients with mental disorders. <i>Breast</i> , 2017, 36, 39-43.	0.9	21
674	FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 253-264.	1.3	25
675	Incidence and prevalence of mental disorders among immigrants and native Finns: a register-based study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2017, 52, 1523-1540.	1.6	48

#	ARTICLE	IF	CITATIONS
676	Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. <i>Psychopharmacology</i> , 2017, 234, 2989-3008.	1.5	14
677	Human neutrophils show decreased survival upon long-term exposure to clozapine. <i>Human Psychopharmacology</i> , 2017, 32, e2629.	0.7	5
678	Combined serum levels of multiple proteins in tPA-BDNF pathway may aid the diagnosis of five mental disorders. <i>Scientific Reports</i> , 2017, 7, 6871.	1.6	27
679	The disconnect between the science on cannabis and public health campaigns. <i>Addiction</i> , 2017, 112, 1882-1883.	1.7	2
680	Systematic review of mental health disorders and intimate partner violence victimisation among military populations. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2017, 52, 1059-1080.	1.6	26
681	Mimetic Theory and the evolutionary paradox of schizophrenia: The archetypal scapegoat hypothesis. <i>Medical Hypotheses</i> , 2017, 108, 101-107.	0.8	4
682	Psychotic-like experiences and happiness in the English general population. <i>Journal of Affective Disorders</i> , 2017, 222, 211-217.	2.0	5
683	Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. <i>Journal of Medical Economics</i> , 2017, 20, 1039-1047.	1.0	17
684	Continuous assessment of schizophrenia using heart rate and accelerometer data. <i>Physiological Measurement</i> , 2017, 38, 1456-1471.	1.2	24
685	Serious delinquency and later schizophrenia: A nationwide register-based follow-up study of Finnish pretrial 15- to 19-year-old offenders sent for a forensic psychiatric examination. <i>European Psychiatry</i> , 2017, 44, 173-178.	0.1	4
686	Clozapine as a Model for Antipsychotic Development. <i>Neurotherapeutics</i> , 2017, 14, 750-761.	2.1	126
687	Longitudinal study of cerebral surface morphology in youth with 22q11.2 deletion syndrome, and association with positive symptoms of psychosis. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017, 58, 305-314.	3.1	11
688	Analysis of Functional Connectivity During an Auditory Oddball Task in Schizophrenia. <i>Biosystems and Biorobotics</i> , 2017, , 751-755.	0.2	1
689	Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 96-101.	0.7	5
690	The Epidemiology of First-Episode Psychosis in Early Intervention in Psychosis Services: Findings From the Social Epidemiology of Psychoses in East Anglia [SEPEA] Study. <i>American Journal of Psychiatry</i> , 2017, 174, 143-153.	4.0	96
691	Gender matters in schizophrenia-spectrum disorders: Results from a healthcare users epidemiological study in Malaga, Spain. <i>Comprehensive Psychiatry</i> , 2017, 72, 136-143.	1.5	12
692	Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis. <i>Psychoneuroendocrinology</i> , 2017, 75, 141-151.	1.3	49
693	Association of <i>NKAPL</i> , <i>TSPAN18</i> , and <i>MPC2</i> gene variants with schizophrenia based on new data and a meta-analysis in Han Chinese. <i>Acta Neuropsychiatrica</i> , 2017, 29, 87-94.	1.0	5

#	ARTICLE	IF	CITATIONS
694	An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. <i>Biological Psychiatry</i> , 2017, 81, 470-477.	0.7	176
695	The Societal Cost of Schizophrenia: A Systematic Review. <i>Pharmacoeconomics</i> , 2017, 35, 25-42.	1.7	133
696	Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence. <i>European Journal of Neuroscience</i> , 2017, 45, 45-57.	1.2	4
697	Genomic approaches to the assessment of human spina bifida risk. <i>Birth Defects Research</i> , 2017, 109, 120-128.	0.8	23
698	Self-Concept Clarity and Psychopathology. , 2017, , 219-242.		15
699	The Global Epidemiology and Disease Burden of Cannabis Use and Dependence. , 2017, , 89-100.		11
700	Acupuncture treatment of a male patient suffering from long-term schizophrenia and sleep disorders. <i>Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</i> , 2017, 37, 862-867.	0.4	6
701	Familial Aggregation and Heritability of Schizophrenia and Co-aggregation of Psychiatric Illnesses in Affected Families. <i>Schizophrenia Bulletin</i> , 2017, 43, 1070-1078.	2.3	51
702	The economic burden of schizophrenia in Malaysia. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1979-1987.	1.0	13
703	Sun Exposure and Psychotic Experiences. <i>Frontiers in Psychiatry</i> , 2017, 8, 107.	1.3	1
704	Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls. <i>Revista Brasileira De Psiquiatria</i> , 2017, 39, 302-308.	0.9	26
705	Schizophrenia and sleep disorders: links, risks, and management challenges. <i>Nature and Science of Sleep</i> , 2017, Volume 9, 227-239.	1.4	124
706	Noradrenergic Modulation of Cognition in Health and Disease. <i>Neural Plasticity</i> , 2017, 2017, 1-14.	1.0	154
707	Neuroimaging Findings in Adolescent Cannabis Use and Early Phase Psychosis. , 2017, , 345-356.		4
708	Use of medical administrative data for the surveillance of psychotic disorders in France. <i>BMC Psychiatry</i> , 2017, 17, 386.	1.1	8
709	Anticholinergic Use and Misuse in Psychiatry: A Comprehensive and Critical Review. <i>Journal of Alcoholism and Drug Dependence</i> , 2017, 05, .	0.2	12
710	Productivity and deadweight losses due to relapses of schizophrenia in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1341-1348.	1.0	3
711	Tumor necrosis factor- α ; and - β ; genetic polymorphisms as a risk factor in Saudi patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1081-1088.	1.0	12

#	ARTICLE	IF	CITATIONS
712	Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. NPJ Schizophrenia, 2018, 4, 4.	2.0	34
713	A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level. Psychological Medicine, 2018, 48, 2101-2115.	2.7	84
714	Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes. Nature Communications, 2018, 9, 838.	5.8	80
715	Psychotic major depression: challenges in clinical practice and research. British Journal of Psychiatry, 2018, 212, 131-133.	1.7	18
716	Co-occurring psychiatric conditions in autism spectrum disorder. International Review of Psychiatry, 2018, 30, 40-61.	1.4	166
717	Alterations of eicosanoids and related mediators in patients with schizophrenia. Journal of Psychiatric Research, 2018, 102, 168-178.	1.5	19
718	Alterations of complex mismatch negativity (cMMN) elicited by a two-tone pattern paradigm in early-phase psychosis. Biological Psychology, 2018, 135, 128-135.	1.1	7
719	Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Current Medical Research and Opinion, 2018, 34, 1377-1388.	0.9	6
720	Evolutionary Perspectives on Genetic and Environmental Risk Factors for Psychiatric Disorders. Annual Review of Clinical Psychology, 2018, 14, 471-493.	6.3	31
721	National Estimates of Recovery-Remission From Serious Mental Illness. Psychiatric Services, 2018, 69, 523-528.	1.1	26
722	Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. Psychiatry Research, 2018, 262, 28-33.	1.7	8
723	Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 84, 71-78.	2.5	22
724	Direct healthcare cost of schizophrenia “ European overview. European Psychiatry, 2018, 48, 79-92.	0.1	31
725	What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry, 2018, 17, 49-66.	4.8	387
726	A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 267-275.	0.7	32
727	Sex differences and the influence of social factors in a Chilean urban psychiatric hospital population. International Journal of Social Psychiatry, 2018, 64, 166-179.	1.6	0
728	Association between celiac disease and schizophrenia: a meta-analysis. European Journal of Gastroenterology and Hepatology, 2018, 30, 442-446.	0.8	15
729	Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. Journal of Affective Disorders, 2018, 229, 177-185.	2.0	25

#	ARTICLE	IF	CITATIONS
730	Identifying first-episode drug naïve patients with schizophrenia with or without auditory verbal hallucinations using whole-brain functional connectivity: A pattern analysis study. <i>NeuroImage: Clinical</i> , 2018, 19, 351-359.	1.4	10
731	Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2018, 102, 245-253.	1.5	102
732	Health conditions, functional status and health care utilization in adults with cerebral palsy. <i>Family Practice</i> , 2018, 35, 661-670.	0.8	38
733	Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan. <i>Journal of Mental Health</i> , 2018, 27, 583-587.	1.0	13
734	Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 737-748.	0.6	10
735	Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. <i>BMJ Open</i> , 2018, 8, e018359.	0.8	17
736	Effect of increasing temperature on daily hospital admissions for schizophrenia in Hefei, China: a time-series analysis. <i>Public Health</i> , 2018, 159, 70-77.	1.4	33
737	ASD and schizophrenia show distinct developmental profiles in common genetic overlap with population-based social communication difficulties. <i>Molecular Psychiatry</i> , 2018, 23, 263-270.	4.1	107
738	Association of Serum Trace Elements with Schizophrenia and Effects of Antipsychotic Treatment. <i>Biological Trace Element Research</i> , 2018, 181, 22-30.	1.9	23
739	Epidemiology of pain and relation to psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 87, 159-167.	2.5	143
740	Recovery from Schizophrenia: An Autoethnography. <i>Deviant Behavior</i> , 2018, 39, 380-399.	1.1	3
741	Imaging genetics of schizophrenia in the post-GWAS era. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 155-165.	2.5	28
742	The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. <i>Psychological Medicine</i> , 2018, 48, 229-244.	2.7	216
743	Interaction between compound genetic risk for schizophrenia and high birth weight contributes to social anhedonia and schizophrenia in women. <i>Psychiatry Research</i> , 2018, 259, 148-153.	1.7	12
744	Risk Factors for Suicidality in Patients With Schizophrenia: A Systematic Review, Meta-analysis, and Meta-regression of 96 Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 787-797.	2.3	118
745	A study in the general population about sadness to disentangle the continuum from well-being to depressive disorders. <i>Journal of Affective Disorders</i> , 2018, 226, 66-71.	2.0	25
746	Schizophrenia in Wolfram Syndrome (DIDMOAD Syndrome): A case report in support of the mitochondrial dysfunction hypothesis. <i>Schizophrenia Research</i> , 2018, 195, 574-575.	1.1	3
747	Cross-cultural psychometric assessment of the VAGUS insight into psychosis scale “ Spanish version. <i>Psychiatry Research</i> , 2018, 259, 450-454.	1.7	2

#	ARTICLE	IF	CITATIONS
748	Maternal immune activation in neurodevelopmental disorders. <i>Developmental Dynamics</i> , 2018, 247, 588-619.	0.8	107
749	Social cognition and self-other distinctions in neuropsychiatry: Insights from schizophrenia and Tourette syndrome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 82, 69-85.	2.5	36
750	The interaction of NOS1AP , DISC1 , DAOA , and GSK3B confers susceptibility of early-onset schizophrenia in Chinese Han population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 187-193.	2.5	14
751	Brain-Behavior Participant Similarity Networks Among Youth and Emerging Adults with Schizophrenia Spectrum, Autism Spectrum, or Bipolar Disorder and Matched Controls. <i>Neuropsychopharmacology</i> , 2018, 43, 1180-1188.	2.8	45
752	Genetic analysis of common variants in the ZNF804A gene with schizophrenia and major depressive disorder. <i>Psychiatric Genetics</i> , 2018, 28, 1-7.	0.6	8
753	The Role of the Primary Care Team. , 0 , 373-385.		0
754	Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report. <i>Sultan Qaboos University Medical Journal</i> , 2018, 18, 208.	0.3	5
755	Combination of G72 Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches. <i>Frontiers in Psychiatry</i> , 2018, 9, 566.	1.3	30
756	Haplotypes of TNFα and IL2 Genes Associated with Sex-Specific Paranoid Schizophrenic Risk in Tunisian Population. <i>Disease Markers</i> , 2018, 2018, 1-12.	0.6	12
757	Factors affecting the occurrence of psychotic symptoms in chronic methamphetamine users. <i>Journal of Addictive Diseases</i> , 2018, 37, 202-210.	0.8	4
758	Psychotic Experiences. , 0 , 286-296.		0
759	Obsessive-Compulsive Inventory-Revised: Factor Structure, Reliability, Validity, and Suicide Risk Screening Characteristics among Nigerian Patients with Schizophrenia. <i>Journal of Neurosciences in Rural Practice</i> , 2018, 09, 219-225.	0.3	2
761	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 833-848.	1.5	83
762	Association on DISC1 SNPs with schizophrenia risk: A meta-analysis. <i>Psychiatry Research</i> , 2018, 270, 306-309.	1.7	11
763	Multiscale network dynamics between heart rate and locomotor activity are altered in schizophrenia. <i>Physiological Measurement</i> , 2018, 39, 115001.	1.2	16
764	Inflammation in individuals with schizophrenia â€“ Implications for neurocognition and daily function. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 296-299.	2.0	33
765	Induced Pluripotent Stem Cells Reveal Common Neurodevelopmental Genome Deprogramming in Schizophrenia. <i>Results and Problems in Cell Differentiation</i> , 2018, 66, 137-162.	0.2	5
766	Schizophrenia and Exercise. , 2018 , 65-82.		0

#	ARTICLE	IF	CITATIONS
767	Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. <i>Clinical Therapeutics</i> , 2018, 40, 1496-1508.	1.1	21
768	Convergence of placenta biology and genetic risk for schizophrenia. <i>Nature Medicine</i> , 2018, 24, 792-801.	15.2	214
769	Sex and gender differences in schizophrenic psychoses—a critical review. <i>Archives of Women's Mental Health</i> , 2018, 21, 627-648.	1.2	140
770	Relationship between incidence and prevalence in psychotic disorders: An incidence-prevalence-mortality model. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1719.	1.1	5
771	The association between problem gambling and psychotic experiences: Findings from the Adult Psychiatric Morbidity Survey 2007. <i>Schizophrenia Research</i> , 2018, 201, 79-84.	1.1	6
772	Determining the incidence of familiarity in ALS. <i>Neurology: Genetics</i> , 2018, 4, e239.	0.9	27
773	Method to estimate the approximate samples size that yield a certain number of significant GWAS signals in polygenic traits. <i>Genetic Epidemiology</i> , 2018, 42, 488-496.	0.6	2
774	Chronic Mental and Neurocognitive Disorders. , 2018, , 103-128.		0
775	Schizophrenia remission without medication. <i>Asian Journal of Psychiatry</i> , 2018, 36, 108-109.	0.9	0
776	Quality of life in Chinese patients with schizophrenia: A meta-analysis. <i>Psychiatry Research</i> , 2018, 268, 392-399.	1.7	19
777	Stress, trauma, and posttraumatic stress disorder in migrants: a comprehensive review. <i>Revista Brasileira De Psiquiatria</i> , 2018, 40, 220-225.	0.9	92
778	Transcranial Direct Current Stimulation, Symptomatology, and Cognition in Psychosis: A Qualitative Review. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 94.	1.0	20
779	Congenital blindness is protective for schizophrenia and other psychotic illness. A whole-population study.. <i>Schizophrenia Research</i> , 2018, 202, 414-416.	1.1	22
780	Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. <i>PLoS ONE</i> , 2018, 13, e0195687.	1.1	313
782	Further evidence for the genetic association between CACNA1I and schizophrenia. <i>Hereditas</i> , 2018, 155, 16.	0.5	14
783	Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. <i>Schizophrenia Bulletin</i> , 2018, 44, 1195-1203.	2.3	875
784	The Role of Cannabis within an Emerging Perspective on Schizophrenia. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 86.	0.7	4
785	Characterization of a Human-Specific Tandem Repeat Associated with Bipolar Disorder and Schizophrenia. <i>American Journal of Human Genetics</i> , 2018, 103, 421-430.	2.6	84

#	ARTICLE	IF	CITATIONS
786	Development of Focused Transcranial Magnetic Stimulation Coils for Treating Schizophrenia. IEEE Transactions on Magnetics, 2018, 54, 1-5.	1.2	4
787	Risk of emergency hospital admission in children associated with mental disorders and alcohol misuse in the household: an electronic birth cohort study. Lancet Public Health, The, 2018, 3, e279-e288.	4.7	31
788	Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research, 2018, 103, 244-251.	1.5	17
789	Neuroepigenetics of Schizophrenia. Progress in Molecular Biology and Translational Science, 2018, 158, 195-226.	0.9	20
790	Autoimmune diseases are associated with an increased risk of schizophrenia: A nationwide population-based cohort study. Schizophrenia Research, 2018, 202, 297-302.	1.1	23
791	Couple therapy, family therapy and systemic interventions for adultâ€œfocused problems: the current evidence base. Journal of Family Therapy, 2019, 41, 492-536.	0.5	74
792	Dysregulated Brain Dynamics in a Triple-Network Saliency Model of Schizophrenia and Its Relation to Psychosis. Biological Psychiatry, 2019, 85, 60-69.	0.7	141
793	Incidence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. Schizophrenia Research, 2019, 204, 458-459.	1.1	5
794	Mental health trajectories among women in Australia as they age. Aging and Mental Health, 2019, 23, 887-896.	1.5	4
795	The prevalence of major mental illness, substance misuse and homelessness in Irish prisoners: systematic review and meta-analyses. Irish Journal of Psychological Medicine, 2019, 36, 35-45.	0.7	20
796	Outcome of serious violent offenders with psychotic illness and cognitive disorder dealt with by the New South Wales criminal justice system. Australian and New Zealand Journal of Psychiatry, 2019, 53, 441-446.	1.3	7
797	Sex differences in the developing brain: insights from multimodal neuroimaging. Neuropsychopharmacology, 2019, 44, 71-85.	2.8	227
798	Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. Nicotine and Tobacco Research, 2019, 21, 357-369.	1.4	26
799	An Overview of Animal Models Related to Schizophrenia. Canadian Journal of Psychiatry, 2019, 64, 5-17.	0.9	138
800	The <i>ANKK1</i> gene and its associated phenotypes: focus on CNS drug response. Pharmacogenomics, 2019, 20, 669-684.	0.6	13
801	Parvalbumin-positive GABAergic interneurons deficit in the hippocampus in Gunn rats: A possible hyperbilirubinemia-induced animal model of schizophrenia. Heliyon, 2019, 5, e02037.	1.4	5
802	Neuropsychiatric phenotypes and a distinct constellation of ASD features in 3q29 deletion syndrome: results from the 3q29 registry. Molecular Autism, 2019, 10, 30.	2.6	38
803	The experiences and meanings of recovery for Swazi women living with â€œschizophreniaâ€œ. Journal of Psychiatric and Mental Health Nursing, 2019, 26, 153-162.	1.2	23

#	ARTICLE	IF	CITATIONS
804	Synthesis, SAR study, and biological evaluation of novel 2,3-dihydro-1H-imidazo[1,2-a]benzimidazole derivatives as phosphodiesterase 10A inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3692-3706.	1.4	5
805	Is there a role for antibodies targeting muscarinic acetylcholine receptors in the pathogenesis of schizophrenia?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 1059-1069.	1.3	7
806	Effectiveness of psycho-education on knowledge regarding schizophrenia and caregiversâ€™ burden among caregivers of patients with schizophrenia â€“ a randomized controlled trial. <i>Family Medicine and Primary Care Review</i> , 2019, 21, 104-111.	0.1	2
807	Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study. <i>JAMA Psychiatry</i> , 2019, 76, 1026.	6.0	51
808	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2019, 76, 1074.	6.0	50
809	Usability evaluation of an eHealth intervention for family carers of individuals affected by psychosis: A mixed-method study. <i>Digital Health</i> , 2019, 5, 205520761987114.	0.9	15
810	Computational Modeling of Genetic Contributions to Excitability and Neural Coding in Layer V Pyramidal Cells: Applications to Schizophrenia Pathology. <i>Frontiers in Computational Neuroscience</i> , 2019, 13, 66.	1.2	5
811	Cannabis and Psychosis Through the Lens of DSM-5. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4149.	1.2	26
812	Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences. <i>Medical Decision Making</i> , 2019, 39, 998-1009.	1.2	5
813	Association of Typical Toxic Heavy Metals with Schizophrenia. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4200.	1.2	17
814	Psychotherapeutische und psychosoziale Interventionen (Modul 4b). , 2019, , 139-180.		0
815	Demographics and Clinical Profiles of Patients Visiting a Free Clinic in Miami, Florida. <i>Frontiers in Public Health</i> , 2019, 7, 212.	1.3	4
816	Randomized controlled trial of adjunctive Valproate for cognitive remediation in early course schizophrenia. <i>Journal of Psychiatric Research</i> , 2019, 118, 66-72.	1.5	9
817	Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View. <i>Frontiers in Psychiatry</i> , 2019, 10, 601.	1.3	22
818	PTSD in prison settings: A systematic review and meta-analysis of comorbid mental disorders and problematic behaviours. <i>PLoS ONE</i> , 2019, 14, e0222407.	1.1	56
819	Psychosocial Stress Induces Schizophrenia-Like Behavior in Mice With Reduced MMP-9 Activity. <i>Frontiers in Behavioral Neuroscience</i> , 2019, 13, 195.	1.0	10
820	Clarifying pathways to poor psychological health: The mediating role of psychosocial factors in the relationship between general psychopathology and quality of life impairment in patients diagnosed with schizophrenia. <i>Journal of Clinical Psychology</i> , 2019, 75, 1022-1033.	1.0	2
821	The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. <i>Psychopharmacology</i> , 2019, 236, 1931-1935.	1.5	20

#	ARTICLE	IF	CITATIONS
822	Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. <i>Health Policy and Technology</i> , 2019, 8, 84-91.	1.3	7
823	Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. <i>Translational Psychiatry</i> , 2019, 9, 19.	2.4	44
824	Assortative Mating on Ancestry-Variant Traits in Admixed Latin American Populations. <i>Frontiers in Genetics</i> , 2019, 10, 359.	1.1	12
825	Quality of Life in Schizophrenia: A Meta-Analysis of Comparative Studies. <i>Psychiatric Quarterly</i> , 2019, 90, 519-532.	1.1	52
826	Synapse Pathology in Schizophrenia: A Meta-analysis of Postsynaptic Elements in Postmortem Brain Studies. <i>Schizophrenia Bulletin</i> , 2020, 46, 374-386.	2.3	77
827	Examining the effects of the histone methyltransferase inhibitor BIX-01294 on histone modifications and gene expression in both a clinical population and mouse models. <i>PLoS ONE</i> , 2019, 14, e0216463.	1.1	16
828	Spatial genome exploration in the context of cognitive and neurological disease. <i>Current Opinion in Neurobiology</i> , 2019, 59, 112-119.	2.0	12
829	MMPs in learning and memory and neuropsychiatric disorders. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3207-3228.	2.4	137
830	Process Development of an Efficient Kilogram-Scale Preparation of a Preferential Dopamine D3 versus D2 Receptor Antagonist SIPI 6398 as a New Antipsychotic Candidate. <i>Organic Process Research and Development</i> , 2019, 23, 1442-1449.	1.3	2
831	The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence. <i>Nutrients</i> , 2019, 11, 1196.	1.7	68
832	New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. <i>Lancet, The</i> , 2019, 394, 240-248.	6.3	767
833	Cognitive impairment and psychosis in schizophrenia: independent or linked conditions?. <i>World Psychiatry</i> , 2019, 18, 162-163.	4.8	25
834	Brain Development and Stochastic Processes During Prenatal and Early Life: You Can't Lose It if You've Never Had It; But It's Better to Have It and Lose It, Than Never to Have Had It at All. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 1042-1050.	0.3	23
836	Cognition and Its Impairment in Schizophrenia and Related Psychotic Disorders. , 2019, , 1-17.		0
839	Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002785.	3.9	45
840	CACNA1C (rs1006737) may be a susceptibility gene for schizophrenia: An updated meta-analysis. <i>Brain and Behavior</i> , 2019, 9, e01292.	1.0	22
841	The Brain That Builds Itself. , 2019, , 18-30.		0
842	Cognitive Enhancement. , 2019, , 31-44.		0

#	ARTICLE	IF	CITATIONS
843	Getting Ready for Cognitive Enhancement. , 2019, , 45-57.		0
844	Computer-based Approaches to Cognitive Enhancement. , 2019, , 58-71.		0
845	Individual and Group Approaches to Cognitive Enhancement. , 2019, , 72-89.		0
846	Psychopharmacological Approaches, Cognitive Enhancement, and Brain Stimulation. , 2019, , 90-102.		1
847	Who Responds Best? Predictors and Moderators of Cognitive Enhancement. , 2019, , 103-114.		0
848	Choosing the Right Treatment for the Right Patient. , 2019, , 115-127.		0
849	Approaches to Assessment and Monitoring Treatment Response. , 2019, , 128-137.		0
850	Research in Cognitive Enhancement. , 2019, , 138-150.		0
853	Assessing whether the association between rheumatoid arthritis and schizophrenia is bidirectional: A nationwide population-based cohort study. Scientific Reports, 2019, 9, 4493.	1.6	12
854	Seasonality of births in horizontal strabismus: comparison with birth seasonality in schizophrenia and other disease conditions. Journal of Developmental Origins of Health and Disease, 2019, 10, 636-644.	0.7	2
855	A randomized controlled trial of mindfulness in patients with schizophrenia. Psychiatry Research, 2019, 275, 137-142.	1.7	24
856	Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology, 2019, 44, 1917-1924.	2.8	24
857	Autoimmune Diseases and Psychotic Disorders. Frontiers in Psychiatry, 2019, 10, 131.	1.3	93
858	Trends in the scientific literature on atypical antipsychotic drugs in the United Kingdom: a bibliometric study. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531882020.	1.2	16
859	Severe mental illness and substance use disorders in prisoners in low-income and middle-income countries: a systematic review and meta-analysis of prevalence studies. The Lancet Global Health, 2019, 7, e461-e471.	2.9	133
860	The Care of Older Adults with Schizophrenia in Developing Countries. , 2019, , 212-222.		0
861	A Systematic Review of the Effect of Probiotic Supplementation on Schizophrenia Symptoms. Neuropsychobiology, 2019, 78, 1-6.	0.9	58
862	Severe mood disorders and schizophrenia in the adult offspring of antenatally depressed mothers in the Northern Finland 1966 Birth Cohort: Relationship to parental severe mental disorder. Journal of Affective Disorders, 2019, 249, 63-72.	2.0	11

#	ARTICLE	IF	CITATIONS
863	Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 179, 55-62.	1.3	5
864	Impaired social behaviour and molecular mediators of associated neural circuits during chronic <i>Toxoplasma gondii</i> infection in female mice. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 88-108.	2.0	28
865	Hypothalamic-pituitary-gonadal axis dysfunction: An innate pathophysiology of schizophrenia?. <i>General and Comparative Endocrinology</i> , 2019, 275, 38-43.	0.8	7
866	Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , 2019, 33, 225-238.	2.7	35
867	Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	0
868	Barriers to care among people with schizophrenia attending a tertiary psychiatric hospital in Nigeria. <i>South African Journal of Psychiatry</i> , 2019, 25, 1392.	0.2	3
869	Mental disorders and intimate partner violence perpetrated by men towards women: A Swedish population-based longitudinal study. <i>PLoS Medicine</i> , 2019, 16, e1002995.	3.9	79
870	The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. <i>BMC Psychiatry</i> , 2019, 19, 370.	1.1	95
871	Biological and practical implications of genome-wide association study of schizophrenia using Bayesian variable selection. <i>NPJ Schizophrenia</i> , 2019, 5, 19.	2.0	0
872	A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 318-328.	0.7	14
873	Bi-directional Mendelian randomization of epithelial ovarian cancer and schizophrenia and uni-directional Mendelian randomization of schizophrenia on circulating 1- or 2-glycerophosphocholine metabolites. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 21, 100539.	0.4	6
874	Crimes by people with schizophrenia in Korea: comparison with the general population. <i>BMC Psychiatry</i> , 2019, 19, 377.	1.1	7
875	Cytokine Alterations in Schizophrenia: An Updated Review. <i>Frontiers in Psychiatry</i> , 2019, 10, 892.	1.3	158
876	Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. <i>Neurobiology of Disease</i> , 2019, 131, 104257.	2.1	131
877	Neural correlates of cognitive deficits across developmental phases of schizophrenia. <i>Neurobiology of Disease</i> , 2019, 131, 104353.	2.1	35
878	Peripheral Biomarkers in Schizophrenia: A Meta-Analysis of Microarray Gene Expression Datasets. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 186-193.	1.0	19
879	Expression Pattern of Long Non-coding RNAs in Schizophrenic Patients. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 211-221.	1.7	39
880	A systematic review of specialist inpatient dementia care services versus standard inpatient dementia care in acute hospitals. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 595-610.	1.4	8

#	ARTICLE	IF	CITATIONS
881	Toxoplasmosis: A pathway to neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 96, 72-92.	2.9	72
882	Hearing loss and incident psychosis in later life: The Health in Men Study (HIMS). <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 408-414.	1.3	8
883	Schizophrenia and gut-flora related epigenetic factors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 90, 49-54.	2.5	11
884	EEG 40 Hz Coherence Decreases in REM Sleep and Ketamine Model of Psychosis. <i>Frontiers in Psychiatry</i> , 2018, 9, 766.	1.3	19
885	Affective and physiological reactivity to emotional comments in individuals at elevated risk for psychosis. <i>Schizophrenia Research</i> , 2019, 206, 428-435.	1.1	11
886	Exome sequencing in families with severe mental illness identifies novel and rare variants in genes implicated in Mendelian neuropsychiatric syndromes. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 11-19.	1.0	31
887	Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 759-767.	2.8	16
888	Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia. <i>Psychiatry Research</i> , 2019, 272, 18-29.	1.7	41
889	“False-positive” self-reported psychotic experiences in the general population: an investigation of outcome, predictive factors and clinical relevance. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 532-543.	1.8	40
890	A Bayesian Approach to Modeling Risk of Hospital Admissions Associated With Schizophrenia Accounting for Underdiagnosis of the Disorder in Administrative Records. <i>Computational Psychiatry</i> , 2020, 2, 1.	1.1	2
891	Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: A case-control study. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 357-367.	1.3	16
892	Candidate metabolic biomarkers for schizophrenia in CNS and periphery: Do any possible associations exist?. <i>Schizophrenia Research</i> , 2020, 226, 95-110.	1.1	20
893	Improvement in depression with oestrogen treatment in women with schizophrenia. <i>Archives of Women's Mental Health</i> , 2020, 23, 149-154.	1.2	10
894	Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review. <i>Nutritional Neuroscience</i> , 2020, 23, 139-148.	1.5	29
895	Prevalence of Self-Reported Intimate Partner Violence Victimization Among Military Personnel: A Systematic Review and Meta-Analysis. <i>Trauma, Violence, and Abuse</i> , 2020, 21, 586-609.	3.9	27
896	Understanding the genetics of neuropsychiatric disorders: the potential role of genomic regulatory blocks. <i>Molecular Psychiatry</i> , 2020, 25, 6-18.	4.1	26
897	Toxoplasmosis and Psychiatric and Neurological Disorders: A Step toward Understanding Parasite Pathogenesis. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2393-2406.	1.7	13
898	Why do High IQ Societies Differ in Intellectual Achievement? The Role of Schizophrenia and Left-Handedness in Per Capita Scientific Publications and Nobel Prizes. <i>Journal of Creative Behavior</i> , 2020, 54, 871-883.	1.6	5

#	ARTICLE	IF	CITATIONS
899	Altered gut microbiota and mucosal immunity in patients with schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2020, 85, 120-127.	2.0	137
900	The Global Epidemiology of Mental and Substance Use Disorders. , 2020, , 15-44.		0
901	Healthcare Costs for People with Serious Mental Illness in England: An Analysis of Costs Across Primary Care, Hospital Care, and Specialist Mental Healthcare. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 177-188.	1.0	24
902	Characterization of Single Gene Copy Number Variants in Schizophrenia. <i>Biological Psychiatry</i> , 2020, 87, 736-744.	0.7	10
903	Schizophrenia—An Overview. <i>JAMA Psychiatry</i> , 2020, 77, 201.	6.0	569
904	Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?. <i>Population Health Management</i> , 2020, 23, 234-242.	0.8	3
905	A review on neural network models of schizophrenia and autism spectrum disorder. <i>Neural Networks</i> , 2020, 122, 338-363.	3.3	101
906	A systematic review of the provision and efficacy of patient and carer information and support (PCIS) interventions for patients with dementia and their informal carers. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 2439-2448.	1.4	4
907	Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2020, 185, 101732.	2.8	159
908	Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 336-343.	1.0	9
909	The connection between microbiome and schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 712-731.	2.9	50
910	Mental health is biological health: Why tackling “diseases of the mind” is an imperative for biological anthropology in the 21st century. <i>American Journal of Physical Anthropology</i> , 2020, 171, 87-117.	2.1	38
911	A novel virtual reality-based theory of mind intervention for outpatients with schizophrenia: A proof-of-concept pilot study. <i>Clinical Psychology and Psychotherapy</i> , 2021, 28, 727-738.	1.4	16
912	Evidence for altered energy metabolism, increased lactate, and decreased pH in schizophrenia brain: A focused review and meta-analysis of human postmortem and magnetic resonance spectroscopy studies. <i>Schizophrenia Research</i> , 2020, 223, 29-42.	1.1	33
913	A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study. <i>Asian Journal of Psychiatry</i> , 2020, 53, 102369.	0.9	8
914	Positive association between PTN polymorphisms and schizophrenia in Northeast Chinese Han population. <i>Psychiatric Genetics</i> , 2020, 30, 141-149.	0.6	4
915	In silico hippocampal modeling for multi-target pharmacotherapy in schizophrenia. <i>NPJ Schizophrenia</i> , 2020, 6, 25.	2.0	8
917	Psychopathology among apprentice traditional health practitioners: A quantitative study from rural KwaZulu-Natal, South Africa. <i>Transcultural Psychiatry</i> , 2021, 58, 486-498.	0.9	7

#	ARTICLE	IF	CITATIONS
918	Gamma transcranial alternating current stimulation in patients with negative symptoms in schizophrenia: A case series. <i>Neurophysiologie Clinique</i> , 2020, 50, 301-304.	1.0	13
919	Genome plasticity and neuropsychiatric disorders. , 2020, , 191-210.		1
920	Adverse childhood experiences during childhood and academic attainment at age 7 and 11 years: an electronic birth cohort study. <i>Public Health</i> , 2020, 189, 37-47.	1.4	8
921	Evidence for Decreased Density of Calretinin-Immunopositive Neurons in the Caudate Nucleus in Patients With Schizophrenia. <i>Frontiers in Neuroanatomy</i> , 2020, 14, 581685.	0.9	13
922	The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus. <i>Neuropsychopharmacology</i> , 2020, 45, 2106-2113.	2.8	10
923	Schizophrenia and Sex Hormones: What Is the Link?. <i>Frontiers in Psychiatry</i> , 2020, 11, 693.	1.3	45
924	Effect of DAOA genetic variation on white matter alteration in corpus callosum in patients with first-episode schizophrenia. <i>Brain Imaging and Behavior</i> , 2021, 15, 1748-1759.	1.1	4
925	The association between resilience and psychosocial functioning in schizophrenia: A systematic review and meta-analysis. <i>Psychiatry Research</i> , 2020, 293, 113374.	1.7	18
926	Investigation of Clozapine and Olanzapine Reactive Metabolite Formation and Protein Binding by Liquid Chromatography-Tandem Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2020, 33, 2420-2431.	1.7	6
927	Efficacy of transcranial direct current stimulation in ameliorating negative symptoms and cognitive impairments in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2020, 224, 2-10.	1.1	30
928	Characterization of dopamine D2 receptor binding, expression and signaling in different brain regions of control and schizophrenia-model Wistar rats. <i>Brain Research</i> , 2020, 1748, 147074.	1.1	10
929	Clinical Off-Label Use of Deep Transcranial Magnetic Stimulation in Psychiatric Conditions. <i>Current Treatment Options in Psychiatry</i> , 2020, 7, 576-588.	0.7	0
930	Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID). <i>Journal of Clinical Pathology</i> , 2020, 73, 587-592.	1.0	27
931	Reducing Shame, Promoting Dignity: A Model for the Primary Prevention of Complex Post-Traumatic Stress Disorder. <i>Trauma, Violence, and Abuse</i> , 2022, 23, 906-919.	3.9	21
932	ZFP804A mutant mice display sex-dependent schizophrenia-like behaviors. <i>Molecular Psychiatry</i> , 2021, 26, 2514-2532.	4.1	21
933	Critical review of the evidence base regarding theories conceptualising the aetiology of psychosis. <i>British Journal of Nursing</i> , 2020, 29, 1030-1037.	0.3	0
934	Exploring the mRNA expression level of RELN in peripheral blood of schizophrenia patients before and after antipsychotic treatment. <i>Hereditas</i> , 2020, 157, 43.	0.5	8
935	An epidemiological survey of mental disorders 5 years after the Lushan earthquake in Ya'an, China. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 1263-1272.	1.6	4

#	ARTICLE	IF	CITATIONS
936	Income, income inequality and schizophrenia in China: a population-based multilevel analysis. <i>Journal of Epidemiology and Community Health</i> , 2020, 74, jech-2019-213049.	2.0	4
937	Association of ADH7 Gene Polymorphism with Schizophrenia in the Han Population of Northern China: a Case-Control Study. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1851-1857.	1.1	0
938	Symptomatic remission affects employment outcomes in schizophrenia patients. <i>BMC Psychiatry</i> , 2020, 20, 219.	1.1	3
939	Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 222, 397-410.	1.1	10
940	Controlled sleep deprivation as an experimental medicine model of schizophrenia: An update. <i>Schizophrenia Research</i> , 2020, 221, 4-11.	1.1	9
941	Avatar Therapy for people with schizophrenia or related disorders. <i>The Cochrane Library</i> , 2020, 5, CD011898.	1.5	17
942	Integrative In Silico Analysis of Genome-Wide DNA Methylation Profiles in Schizophrenia. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1887-1893.	1.1	10
943	Prevalence of intimate partner violence perpetration among military populations: A systematic review and meta-analysis. <i>Aggression and Violent Behavior</i> , 2020, 53, 101419.	1.2	46
944	A functional missense variant in ITIH3 affects protein expression and neurodevelopment and confers schizophrenia risk in the Han Chinese population. <i>Journal of Genetics and Genomics</i> , 2020, 47, 233-248.	1.7	10
945	Gender difference in the association between education and schizophrenia in Chinese adults. <i>BMC Psychiatry</i> , 2020, 20, 296.	1.1	13
946	Multiple functional connectivity networks fusion for schizophrenia diagnosis. <i>Medical and Biological Engineering and Computing</i> , 2020, 58, 1779-1790.	1.6	12
947	Disordered directional brain network interactions during learning dynamics in schizophrenia revealed by multivariate autoregressive models. <i>Human Brain Mapping</i> , 2020, 41, 3594-3607.	1.9	16
948	Montreal Cognitive Assessment for evaluating the cognitive impairment in patients with schizophrenia: A systematic review. <i>General Hospital Psychiatry</i> , 2020, 65, 64-73.	1.2	22
949	Clinical outcomes among individuals with a first episode psychosis attending Butabika National Mental Referral Hospital in Uganda: a longitudinal cohort study. A study protocol for a longitudinal cohort study. <i>BMJ Open</i> , 2020, 10, e034367.	0.8	2
950	Lack of Helios During Neural Development Induces Adult Schizophrenia-Like Behaviors Associated With Aberrant Levels of the TRIF-Recruiter Protein WDFY1. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 93.	1.8	6
951	Effect of ZNF804A gene polymorphism (rs1344706) on the plasticity of the functional coupling between the right dorsolateral prefrontal cortex and the contralateral hippocampal formation. <i>NeuroImage: Clinical</i> , 2020, 27, 102279.	1.4	7
952	Community perceptions of barriers to management of chronic psychotic disorders and knowledge and attitudes about long-acting injectable antipsychotic medication: qualitative study in Dar es Salaam, Tanzania. <i>BJPsych Open</i> , 2020, 6, e27.	0.3	7
953	Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. <i>CNS Drugs</i> , 2020, 34, 473-507.	2.7	38

#	ARTICLE	IF	CITATIONS
955	Recent advances in the development of asenapine formulations. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1377-1393.	2.4	6
956	Prevalence of Suicidality in the European General Population: A Systematic Review and Meta-Analysis. <i>Archives of Suicide Research</i> , 2021, 25, 810-828.	1.2	33
957	Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1058-1071.	1.7	7
958	Nonmedical Interventions for Schizophrenia. <i>Holistic Nursing Practice</i> , 2020, 34, 73-82.	0.3	3
959	A Public Health Perspective on Screening for Psychosis Within General Practice Clinics. <i>Frontiers in Psychiatry</i> , 2019, 10, 1025.	1.3	11
960	Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring. <i>Scientific Reports</i> , 2020, 10, 1219.	1.6	2
961	Parietal memory network and default mode network in first-episode drug-naïve schizophrenia: Associations with auditory hallucination. <i>Human Brain Mapping</i> , 2020, 41, 1973-1984.	1.9	8
962	At-risk mental states. , 2020, , 47-57.		5
963	Face pareidolia in schizophrenia. <i>Schizophrenia Research</i> , 2020, 218, 138-145.	1.1	16
964	Cannabis and the adolescent brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7-11.	3.3	10
965	A conceptualized model linking matrix metalloproteinase-9 to schizophrenia pathogenesis. <i>Schizophrenia Research</i> , 2020, 218, 28-35.	1.1	24
966	The prevalence and associated factors of depression among patients with schizophrenia in Addis Ababa, Ethiopia, cross-sectional study. <i>BMC Psychiatry</i> , 2020, 20, 3.	1.1	7
967	Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study. <i>British Journal of Psychiatry</i> , 2020, 217, 450-457.	1.7	15
968	Using the tools of genetic epidemiology to understand sex differences in neuropsychiatric disorders. <i>Genes, Brain and Behavior</i> , 2020, 19, e12660.	1.1	41
969	Glutamate metabolites in treatment resistant schizophrenia: A meta-analysis and systematic review of 1H-MRS studies. <i>Psychiatry Research - Neuroimaging</i> , 2020, 300, 111080.	0.9	10
970	Area deprivation, urbanicity, severe mental illness and social drift – A population-based linkage study using routinely collected primary and secondary care data. <i>Schizophrenia Research</i> , 2020, 220, 130-140.	1.1	26
971	Overdispersed gene expression in schizophrenia. <i>NPJ Schizophrenia</i> , 2020, 6, 9.	2.0	20
972	Vitamin D deficiency and Schizophrenia in Adults: A Systematic Review and Meta-analysis of Observational Studies. <i>Psychiatry Research</i> , 2020, 288, 112959.	1.7	27

#	ARTICLE	IF	CITATIONS
973	Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. <i>BMC Psychiatry</i> , 2020, 20, 149.	1.1	37
974	Correlation Analysis of the Quality of Family Functioning and Subjective Quality of Life in Rehabilitation Patients Living with Schizophrenia in the Community. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2481.	1.2	5
975	Postnatal functional inactivation of the ventral subiculum enhances dopaminergic responses in the core part of the nucleus accumbens following ketamine injection in adult rats. <i>Neurochemistry International</i> , 2020, 137, 104736.	1.9	3
976	Action Monitoring Alterations as Indicators of Predictive Deficits in Schizophrenia. <i>Topics in Cognitive Science</i> , 2021, 13, 142-163.	1.1	7
977	Brain activity and connectivity differences in reward value discrimination during effort computation in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 647-659.	1.8	3
978	Genetic risks of schizophrenia identified in a matched case-control study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 775-781.	1.8	3
979	Inflammatory and cardiometabolic markers at presentation with first episode psychosis and long-term clinical outcomes: A longitudinal study using electronic health records. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 117-127.	2.0	13
980	Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110084.	2.5	7
981	Kava decreases the stereotyped behavior induced by amphetamine in mice. <i>Journal of Ethnopharmacology</i> , 2021, 265, 113293.	2.0	6
982	Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 15-26.	1.5	14
983	Co-morbidity between mood and anxiety disorders: A systematic review and meta-analysis. <i>Depression and Anxiety</i> , 2021, 38, 286-306.	2.0	73
984	Deconstructing Negative Symptoms in Individuals at Clinical High-Risk for Psychosis: Evidence for Volitional and Diminished Emotionality Subgroups That Predict Clinical Presentation and Functional Outcome. <i>Schizophrenia Bulletin</i> , 2021, 47, 54-63.	2.3	23
985	Psychotic Disorders and Risk-States in Adolescence: Etiology, Developmental Considerations, and Treatment. , 2021, , .		0
987	Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders. <i>Movement Disorders</i> , 2021, 36, 1353-1361.	2.2	23
988	First-Episode & Early Psychosis in Transition-Age Youth. , 2021, , 277-310.		0
989	Analysis of the early mother-child relationship in schizophrenic patients. <i>International Journal of Social Psychiatry</i> , 2022, 68, 548-554.	1.6	8
990	Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study. <i>Metabolites</i> , 2021, 11, 34.	1.3	7
991	Psychotropic drug prescription patterns and their predictors among older adult patients with schizophrenia in a tertiary-referral psychiatric hospital. <i>Taiwanese Journal of Psychiatry</i> , 2021, 35, 70.	0.1	0

#	ARTICLE	IF	CITATIONS
992	Does Hippocampal Volume Predict Transition to Psychosis in a High-Risk Group? A Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2020, 11, 614659.	1.3	12
994	Economic Impact of Schizophrenia from a Hospital and Social Security System Perspective in Italy. <i>Clinical Drug Investigation</i> , 2021, 41, 183-191.	1.1	4
995	Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: A Korean national cohort study. <i>Schizophrenia Research</i> , 2021, 228, 417-424.	1.1	15
996	Novel Synthetic Routes to Prepare Biologically Active Quinoxalines and Their Derivatives: A Synthetic Review for the Last Two Decades. <i>Molecules</i> , 2021, 26, 1055.	1.7	39
997	Case Report: Feasibility of a Novel Virtual Reality-Based Intervention for Patients With Schizophrenia. <i>Frontiers in Psychology</i> , 2021, 12, 642590.	1.1	4
998	Family relationships and personality disorder functioning styles in paranoid schizophrenia. <i>Personality and Individual Differences</i> , 2021, 169, 109844.	1.6	0
999	Misdiagnosis, detection rate, and associated factors of severe psychiatric disorders in specialized psychiatry centers in Ethiopia. <i>Annals of General Psychiatry</i> , 2021, 20, 10.	1.2	32
1000	Systematic review and meta-analysis of the prevalence of depressive symptoms, dysthymia and major depressive disorders among homeless people. <i>BMJ Open</i> , 2021, 11, e040061.	0.8	19
1001	Using Antipsychotic non-Adherence Model to Explain the Profile of Non-adherence to Treatment among Patients with Schizophrenia in Zanzibar: A Protocol for Mixed Method Study (Preprint). <i>JMIR Research Protocols</i> , 0, , .	0.5	0
1002	Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113155.	2.6	5
1003	The Impact of PER3 VNTR Polymorphism on the Development of Schizophrenia in a Turkish Population. <i>Cytology and Genetics</i> , 2021, 55, 188-193.	0.2	2
1004	Morbidity and mortality in schizophrenia with comorbid substance use disorders. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 42-49.	2.2	25
1005	Steroid disulfates - Sulfation double trouble. <i>Molecular and Cellular Endocrinology</i> , 2021, 524, 111161.	1.6	9
1006	Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1 β levels in patients with schizophrenia spectrum disorder and their siblings. <i>Schizophrenia Research</i> , 2021, 229, 27-37.	1.1	14
1007	Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 595-607.	1.8	40
1008	Language evolution: examining the link between cross-modality and aggression through the lens of disorders. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2021, 376, 20200188.	1.8	12
1009	An Investigation of Dopamine's Role in Six Psychiatric Illnesses. <i>Journal of Student Research</i> , 2021, 10, .	0.0	0
1010	Digital Technologies for Schizophrenia Management: A Descriptive Review. <i>Science and Engineering Ethics</i> , 2021, 27, 25.	1.7	27

#	ARTICLE	IF	CITATIONS
1011	Multi-spatial-scale dynamic interactions between functional sources reveal sex-specific changes in schizophrenia. <i>Network Neuroscience</i> , 2022, 6, 357-381.	1.4	29
1012	Prevalence of Circadian Rhythm Sleep-Wake Disorder in Outpatients with Schizophrenia and Its Association with Psychopathological Characteristics and Psychosocial Functioning. <i>Journal of Clinical Medicine</i> , 2021, 10, 1513.	1.0	5
1013	A missense variant in <i>NDUFA6</i> confers schizophrenia risk by affecting YY1 binding and NAGA expression. <i>Molecular Psychiatry</i> , 2021, 26, 6896-6911.	4.1	19
1014	Genome wide association study identifies four loci for early onset schizophrenia. <i>Translational Psychiatry</i> , 2021, 11, 248.	2.4	15
1016	Increased in-hospital mortality from COVID-19 in patients with schizophrenia. <i>L'Encephale</i> , 2021, 47, 89-95.	0.3	33
1017	Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update. <i>Current Neuropharmacology</i> , 2021, 19, 641-664.	1.4	18
1018	Advanced EEG-based learning approaches to predict schizophrenia: Promises and pitfalls. <i>Artificial Intelligence in Medicine</i> , 2021, 114, 102039.	3.8	54
1020	Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis. <i>Scientific Reports</i> , 2021, 11, 7527.	1.6	9
1021	Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia. <i>Schizophrenia Research</i> , 2021, 231, 179-188.	1.1	6
1022	WEVar: a novel statistical learning framework for predicting noncoding regulatory variants. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	5
1023	Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2022, 220, 115-120.	1.7	81
1024	Deep learning applied to electroencephalogram data in mental disorders: A systematic review. <i>Biological Psychology</i> , 2021, 162, 108117.	1.1	32
1025	TMS-EEG Research to Elucidate the Pathophysiological Neural Bases in Patients with Schizophrenia: A Systematic Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 388.	1.1	14
1026	Evolution in schizophrenia diagnosis in the department of Caldas, Colombia. 2010-2015. <i>Revista Facultad De Medicina</i> , 2021, 69, e73159.	0.0	0
1027	Response to the Letter to the Editor concerning "Evolutionary puzzle of <i>Toxoplasma gondii</i> with suicidal ideation and suicide attempts: An updated systematic review and meta-analysis" by Amouei et al. (<i>Transbound Emerg Dis</i> ; 2020: https://doi.org/10.1111/tbed.13550). <i>Transboundary and Emerging Diseases</i> , 2021, 68, 2990-2992.	1.3	0
1028	Need for Ethnic and Population Diversity in Psychosis Research. <i>Schizophrenia Bulletin</i> , 2021, 47, 889-895.	2.3	25
1029	The temporal sensitivity to the tactile-induced double flash illusion mediates the impact of beta oscillations on schizotypal personality traits. <i>Consciousness and Cognition</i> , 2021, 91, 103121.	0.8	9
1030	Gluten and FODMAPs Relationship with Mental Disorders: Systematic Review. <i>Nutrients</i> , 2021, 13, 1894.	1.7	3

#	ARTICLE	IF	CITATIONS
1031	Sex Selection Bias in Schizophrenia Antipsychotic Trials—An Update Systematic Review. <i>Women</i> , 2021, 1, 97-108.	0.5	1
1032	A Deformation-Based Shape Study of the Corpus Callosum in First Episode Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 621515.	1.3	2
1033	Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. <i>Pharmaceutics</i> , 2021, 13, 935.	2.0	14
1034	Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. <i>Health Psychology Research</i> , 2021, 9, 24932.	0.6	5
1036	Association between cognitive impairment and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. <i>Aging</i> , 2021, 13, 16353-16366.	1.4	7
1038	Effects of mild-intensity physical exercise on neurocognition in inpatients with schizophrenia: A pilot randomized controlled trial. <i>Perspectives in Psychiatric Care</i> , 2022, 58, 1037-1047.	0.9	9
1039	Histamine, Neuroinflammation and Neurodevelopment: A Review. <i>Frontiers in Neuroscience</i> , 2021, 15, 680214.	1.4	32
1040	Involvement of Gut Microbiota in Schizophrenia and Treatment Resistance to Antipsychotics. <i>Biomedicines</i> , 2021, 9, 875.	1.4	21
1041	Still “being bothered about Billy”: managing the physical health of people with severe mental illness. <i>British Journal of General Practice</i> , 2021, 71, 373-376.	0.7	6
1042	Diffusion MRI derived free-water imaging measures in patients with schizophrenia and their non-psychotic siblings. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110238.	2.5	3
1043	Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. <i>CNS Drugs</i> , 2021, 35, 999-1008.	2.7	6
1044	What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3411-3423.	2.0	8
1045	Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. <i>Molecular Psychiatry</i> , 2021, 26, 7661-7670.	4.1	18
1046	Acknowledging Patient Heterogeneity in Economic Evaluations in Schizophrenia: A Systematic Review. <i>Value in Health</i> , 2022, 25, 147-156.	0.1	2
1047	Genome-wide association study followed by trans-ancestry meta-analysis identify 17 new risk loci for schizophrenia. <i>BMC Medicine</i> , 2021, 19, 177.	2.3	12
1048	“Blessed are the Nations with High Levels of Schizophrenia”: National Level Schizophrenia Prevalence and Its Relationship with National Levels of Religiosity. <i>Journal of Religion and Health</i> , 2021, , 1.	0.8	2
1049	The prevalence, incidence, and admission rate of diagnosed schizophrenia spectrum disorders in Korea, 2008–2017: A nationwide population-based study using claims big data analysis. <i>PLoS ONE</i> , 2021, 16, e0256221.	1.1	7
1050	Risk factors for early-phase clozapine discontinuation: A nested case-control study. <i>Asian Journal of Psychiatry</i> , 2021, 62, 102745.	0.9	1

#	ARTICLE	IF	CITATIONS
1051	Psychotic-like experiences among 9,564 Kenyan adolescents and young adults. <i>Psychiatry Research</i> , 2021, 302, 113994.	1.7	15
1052	Serum level of high sensitive C-reactive protein and IL-6 markers in patients with treatment-resistant schizophrenia in Ethiopia: a comparative study. <i>BMC Psychiatry</i> , 2021, 21, 428.	1.1	7
1053	Narrative identity in the psychosis spectrum: A systematic review and developmental model. <i>Clinical Psychology Review</i> , 2021, 88, 102067.	6.0	21
1054	Current and Future Trends in Hospital Utilization of Patients With Schizophrenia in Korea: A Time Series Analysis Using National Health Insurance Data. <i>Psychiatry Investigation</i> , 2021, 18, 795-800.	0.7	7
1055	MAD1L1 and TSNARE gene polymorphisms are associated with schizophrenia susceptibility in the Han Chinese population. <i>BMC Medical Genomics</i> , 2021, 14, 218.	0.7	8
1056	Association between rs1344706 Polymorphism in the ZNF804A Gene and the Risk for Schizophrenia. <i>Iranian Journal of Psychiatry</i> , 2021, 16, 383-388.	0.4	2
1057	Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies. <i>Annals of General Psychiatry</i> , 2021, 20, 41.	1.2	4
1058	Cross-sectional analysis of coding, patient characteristics, consultation frequency and pharmacological treatment of adults with severe mental disorders in Irish general practice. <i>Irish Journal of Medical Science</i> , 2022, 191, 1785-1793.	0.8	1
1059	Neurocognition in Kenyan youth at clinical high risk for psychosis. <i>Schizophrenia Research: Cognition</i> , 2021, 25, 100198.	0.7	2
1060	A perspective on the potential involvement of impaired proteostasis in neuropsychiatric disorders. <i>Biological Psychiatry</i> , 2021, , .	0.7	5
1061	Genetic association of DISC1 variant rs3738401 with susceptibility to Schizophrenia risk in North Indian population. <i>Meta Gene</i> , 2021, 29, 100923.	0.3	0
1062	Prevalence of schizophrenia and its association with socio-demographic correlates in an agricultural region of China. <i>Asian Journal of Psychiatry</i> , 2021, 64, 102743.	0.9	7
1063	Ameliorating schizophrenia-like symptoms in vasopressin deficient male Brattleboro rat by chronic antipsychotic treatment. <i>European Journal of Pharmacology</i> , 2021, 909, 174383.	1.7	5
1064	Post-schizophrenia comorbid depressive disorder and insomnia treated by acupuncture combined with Chinese medicine: A retrospective case series based on JBI reporting checklist. <i>World Journal of Acupuncture-moxibustion</i> , 2021, 31, 314-319.	0.1	1
1065	Does the gut microbiome partially mediate the impact of air pollutants exposure on liver function? Evidence based on schizophrenia patients. <i>Environmental Pollution</i> , 2021, 291, 118135.	3.7	24
1066	Contribution of neuroinflammation, resolution, and neuroprotection in neuropsychiatric diseases. , 2022, , 161-186.		0
1067	Impact of aerobic exercise on cognitive function in patients with schizophrenia during daily nursing. <i>Medicine (United States)</i> , 2021, 100, e23876.	0.4	1
1068	OUP accepted manuscript. <i>Schizophrenia Bulletin</i> , 2021, , .	2.3	5

#	ARTICLE	IF	CITATIONS
1069	Psychotic Experiences and Hikikomori in a Nationally Representative Sample of Adult Community Residents in Japan: A Cross-Sectional Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 602678.	1.3	7
1070	Application of deep and machine learning techniques for multi-label classification performance on psychotic disorder diseases. <i>Informatics in Medicine Unlocked</i> , 2021, 23, 100545.	1.9	21
1071	Genetic and clinical analyses of psychosis spectrum symptoms in a large multiethnic youth cohort reveal significant link with ADHD. <i>Translational Psychiatry</i> , 2021, 11, 80.	2.4	11
1074	Psychotic Disorders and Bipolar Affective Disorder. , 0, , 9-35.		1
1077	The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism. <i>Autism Research</i> , 2020, 13, 641-654.	2.1	7
1078	Psychisch kranke Rechtsbrecher. , 2006, , 254-270.		5
1080	A Neurodevelopmental Perspective on Hallucinations. , 2013, , 203-230.		2
1081	Brain Morphometry: Schizophrenia. <i>Neuromethods</i> , 2018, , 323-338.	0.2	1
1082	Pharmacogenomics Applications in Psychiatric Disorders. <i>Methods in Pharmacology and Toxicology</i> , 2008, , 369-394.	0.1	1
1083	Dopamine Receptors and the Treatment of Schizophrenia. <i>Receptors</i> , 2010, , 431-477.	0.2	7
1084	Assessment of Risk for Psychosis. , 2019, , 7-40.		3
1085	Brief Intervention Models in Psychosis for Developing Countries (Asia and Africa). , 2016, , 191-204.		3
1086	Neuropathological Background of MK-801 for Inducing Murine Model of Schizophrenia. , 2017, , 337-354.		2
1087	The Effect of 17 β -Estradiol and Its Analogues on Cognition in Preclinical and Clinical Research: Relevance to Schizophrenia. , 2017, , 355-374.		4
1088	Overview of Descriptive Epidemiology of Mental Disorders. <i>Handbooks of Sociology and Social Research</i> , 2013, , 169-182.	0.1	13
1089	Urban-Rural Differences in Major Mental Health Conditions. <i>Mental Health and Illness Worldwide</i> , 2016, , 1-106.	0.1	4
1090	Urban-Rural Differences in Major Mental Health Conditions. <i>Mental Health and Illness Worldwide</i> , 2017, , 27-132.	0.1	12
1091	Free viewing exploration in schizophrenia: Review of evidence from laboratory settings to natural environment. <i>L'Encephale</i> , 2020, 46, 115-122.	0.3	4

#	ARTICLE	IF	CITATIONS
1093	Harm Reduction Policies for Cannabis. , 2014, , 692-709.		1
1099	Multikernel Capsule Network for Schizophrenia Identification. IEEE Transactions on Cybernetics, 2022, 52, 4741-4750.	6.2	28
1100	Aberrant Expression of Long Non-Coding RNAs in Schizophrenia Patients. Medical Science Monitor, 2016, 22, 3340-3351.	0.5	37
1101	Regulatory Role of lncRNA NONHSAT089447 in the Dopamine Signaling Pathway in Schizophrenic Patients. Medical Science Monitor, 2019, 25, 4322-4332.	0.5	12
1102	Advances in clinical staging, early intervention, and the prevention of psychosis. F1000Research, 2019, 8, 2027.	0.8	14
1103	Strategies for pharmacotherapy of schizophrenia. Drugs of the Future, 2008, 33, 0777.	0.0	17
1104	A Novel Approach to Determining Violence Risk in Schizophrenia: Developing a Stepped Strategy in 13,806 Discharged Patients. PLoS ONE, 2012, 7, e31727.	1.1	25
1105	Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families. PLoS ONE, 2012, 7, e52262.	1.1	5
1106	Meta-Analysis Indicates That the European GWAS-Identified Risk SNP rs1344706 within ZNF804A Is Not Associated with Schizophrenia in Han Chinese Population. PLoS ONE, 2013, 8, e65780.	1.1	26
1107	Mortality among People with Severe Mental Disorders Who Reach Old Age: A Longitudinal Study of a Community-Representative Sample of 37892 Men. PLoS ONE, 2014, 9, e111882.	1.1	67
1108	GSTM1/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients. PLoS ONE, 2017, 12, e0183812.	1.1	21
1109	Association between latent toxoplasmosis and clinical course of schizophrenia - continuous course of the disease is characteristic for Toxoplasma gondii-infected patients. Folia Parasitologica, 2015, 62, .	0.7	20
1110	Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis. Journal of Psychiatry and Neuroscience, 2018, 43, 194-200.	1.4	27
1111	Schizophrenia and COVID-19: risks and recommendations. Revista Brasileira De Psiquiatria, 2020, 42, 236-238.	0.9	77
1112	Evaluation of nonadherence to treatment among patients with schizophrenia attending psychosocial care centers in the south region of Brazil. Trends in Psychiatry and Psychotherapy, 2020, 42, 223-229.	0.4	2
1113	Global Burden of Mental, Neurological, and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. , 2016, , 29-40.		16
1114	Adult Mental Disorders. , 2016, , 67-86.		3
1115	Clinical Factors Associated with New-Onset Glucose Intolerance among Patients with Schizophrenia during Clozapine Treatment: All-Case Surveillance in Japan. Tohoku Journal of Experimental Medicine, 2020, 252, 177-183.	0.5	1

#	ARTICLE	IF	CITATIONS
1116	Treatment-Resistant Schizophrenia: Terminology and Clinical Features. Korean Journal of Schizophrenia Research, 2020, 23, 45-50.	0.3	2
1117	Revisi3n cr4tica de las fuentes de variabilidad en la medici3n de la prevalencia de esquizofrenia. Salud Mental, 2014, 37, 127.	0.3	9
1118	Automatic Detection of Incoherent Speech for Diagnosing Schizophrenia. , 2018, , .		49
1119	<p>Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective</p>. Drug Design, Development and Therapy, 2020, Volume 14, 5559-5574.	2.0	11
1120	N-acetyl-cysteine in Schizophrenia: Potential Role on the Sensitive Cysteine Proteome. Current Medicinal Chemistry, 2020, 27, 6424-6439.	1.2	5
1121	Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems. Current Neuropharmacology, 2015, 13, 435-444.	1.4	19
1122	Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. Current Neuropharmacology, 2018, 16, 583-606.	1.4	72
1123	Schizophrenia: from Epidemiology to Rehabilitation. Clinical Practice and Epidemiology in Mental Health, 2012, 8, 52-66.	0.6	34
1124	Epidemiology and Treatment Guidelines of Negative Symptoms in Schizophrenia in Central and Eastern Europe: A Literature Review. Clinical Practice and Epidemiology in Mental Health, 2015, 11, 158-165.	0.6	13
1125	Quantifying the Language of Schizophrenia in Social Media. , 2015, , .		96
1126	Habenula deep brain stimulation for intractable schizophrenia: a pilot study. Neurosurgical Focus, 2020, 49, E9.	1.0	35
1127	Pharmacogenetics of antipsychotic-induced side effects. Dialogues in Clinical Neuroscience, 2009, 11, 405-415.	1.8	50
1128	The epidemiology of schizophrenia: replacing dogma with knowledge. Dialogues in Clinical Neuroscience, 2010, 12, 305-315.	1.8	97
1130	Comparing Copper Serum Level and Cognitive Functioning in Patients With Schizophrenia and Healthy Controls. Basic and Clinical Neuroscience, 2020, 11, 649-658.	0.3	7
1131	Do higher primary care practice performance scores predict lower rates of emergency admissions for persons with serious mental illness? An analysis of secondary panel data. Health Services and Delivery Research, 2015, 3, 1-68.	1.4	6
1132	The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study. Health Services and Delivery Research, 2020, 8, 1-126.	1.4	2
1133	Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial. Health Technology Assessment, 2016, 20, 1-100.	1.3	20
1134	Toxicity, Deficiency and Dysmetabolism of Trace Elements in Ghanaian Clinically Stable Schizophrenics. Open Access Macedonian Journal of Medical Sciences, 2014, 2, 293-298.	0.1	3

#	ARTICLE	IF	CITATIONS
1135	Genetics of schizophrenia (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 3462-3468.	0.8	16
1136	Predictive factors in early onset schizophrenia. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	9
1137	Early Intervention for Psychosis: The Recovery After an Initial Schizophrenia Episode Project. <i>Psychiatric Annals</i> , 2015, 45, 548-553.	0.1	19
1139	Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 568-575.	1.1	148
1140	Psychotic Disorders in Children and Adolescents: A Primer on Contemporary Evaluation and Management. <i>primary care companion for CNS disorders, The</i> , 2014, 16, .	0.2	22
1141	A study on mental disorders: 5-year retrospective study. <i>Journal of Family Medicine and Primary Care</i> , 2014, 3, 12.	0.3	7
1142	Methylenetetrahydrofolate reductase A1298C genetic variant& risk of schizophrenia: A meta-analysis. <i>Indian Journal of Medical Research</i> , 2017, 145, 437-447.	0.4	10
1143	The Infection Hypothesis of Schizophrenia: A Systematic Review. <i>Journal of Behavioral and Brain Science</i> , 2011, 01, 47-56.	0.2	2
1144	Patient Reported Outcomes Instruments in Schizophrenia: A Review of Psychometric Properties. <i>Open Journal of Medical Psychology</i> , 2014, 03, 141-156.	0.1	8
1145	Increased breath ethane and pentane concentrations in currently unmedicated patients with schizophrenia. <i>Open Journal of Psychiatry</i> , 2011, 01, 1-7.	0.2	14
1146	Social Aspects of the Quality of Life of Persons Suffering from Schizophrenia. <i>Open Journal of Psychiatry</i> , 2016, 06, 50-60.	0.2	5
1147	Factors Affecting Treatment Discontinuation and Treatment Outcome in Patients with Schizophrenia in Korea: 10-Year Follow-Up Study. <i>Psychiatry Investigation</i> , 2011, 8, 22.	0.7	12
1148	Prevalence and Correlates of DSM-IV Mental Disorders in South Korean Adults: The Korean Epidemiologic Catchment Area Study 2011. <i>Psychiatry Investigation</i> , 2015, 12, 164.	0.7	101
1149	Dental implants placement in paranoid squizofrenic patient with obsessive-compulsive disorder: A case report. <i>Journal of Clinical and Experimental Dentistry</i> , 2017, 9, 0-0.	0.5	1
1150	Non conventional psychiatric rehabilitation in schizophrenia using therapeutic riding: the FISE multicentre Pindar project. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2011, 47, 409-14.	0.2	17
1151	Family-Based Whole-Exome Sequencing for Identifying Novel Variants in Consanguineous Families with Schizophrenia. <i>Iranian Red Crescent Medical Journal</i> , 2016, 19, .	0.5	2
1152	Prevalence of schizophrenia in China between 1990 and 2010. <i>Journal of Global Health</i> , 2015, 5, 010410.	1.2	37
1153	Selection and evaluation of reference genes for analysis of mouse <i>(Mus musculus)</i> sex-dimorphic brain development. <i>PeerJ</i> , 2017, 5, e2909.	0.9	22

#	ARTICLE	IF	CITATIONS
1154	Expression of schizophrenia biomarkers in extraocular muscles from patients with strabismus: an explanation for the link between exotropia and schizophrenia?. PeerJ, 2017, 5, e4214.	0.9	6
1155	Assessing cardiovascular risk in patients with severe mental illness. Nursing Standard (Royal College) Tj ETQq1 1 0.784314 rgBT /Overlo	0.1	1
1156	Clozapine underutilization in treatment-resistant schizophrenia. Mental Health Clinician, 2015, 5, 63-67.	0.5	1
1157	Optimization of Neurite Tracing and Further Characterization of Human Monocyte-Derived-Neuronal-like Cells. Brain Sciences, 2021, 11, 1372.	1.1	5
1158	Wie verlaufen Schizophrenien?. , 2004, , 49-61.		0
1160	Gender differences among schizophrenic patients admitted to the psychiatric emergency room. Jornal Brasileiro De Psiquiatria, 2009, 58, 267-268.	0.2	0
1161	Prediction of Psychosis Through the Prodromal Syndrome. , 2010, , 251-266.		0
1162	Impact of Contextual Environmental Mechanisms on the Incidence of Schizophrenia and Other Psychoses. , 2010, , 67-96.		1
1163	Chapter 16Mental Disorders. , 2010, , .		0
1164	Gap Junctions and the Notion of Electrical Coupling Between Axons. , 2010, , 212-243.		0
1165	Cerebellar Ataxia. , 2010, , 152-177.		0
1167	Epileptiform Discharges In Vitro. , 2010, , 302-312.		0
1169	Cortical Neurons and Their Models. , 2010, , 179-211.		0
1171	Persistent Gamma Oscillations. , 2010, , 282-301.		0
1172	Very Fast Oscillations. , 2010, , 245-268.		0
1175	Historical Prelude. , 2010, , 16-30.		0
1176	Beta-2 Oscillations. , 2010, , 269-281.		0
1177	Overview of In Vivo Cortical Oscillations. , 2010, , 31-69.		0

#	ARTICLE	IF	CITATIONS
1178	The psychosis epidemiology in Turkey: A systematic review on prevalence estimates and admission rates. Turk Psikiyatri Dergisi, 2011, , .	0.2	9
1180	Psychotic disorders among immigrants from Turkey in Western Europe: An overview of incidence and prevalence estimates, and admission rates. Turk Psikiyatri Dergisi, 2011, , .	0.2	1
1181	Schizophrenia Has a High Heritability, but Where Are the Genes?. , 2011, , 219-236.		0
1182	Sant� mentale, pr�carit� et pratiques des m�decins g�n�ralistes, enqu�te en Centres de sant� de Grenoble. Sante Publique, 2012, Vol. 23, 97-111.	0.0	0
1183	Brain Evolution and Cognition: Psychosis as Evolutionary Cost for Complexity and Cognitive Abilities in Humans. , 2011, , 1-17.		1
1185	Schizophrenia and paranoid disorders in late life. , 2012, , 1546-1550.		0
1187	Quick Reference. , 2013, , 157-175.		0
1188	Umsatzver�nderungen in einzelnen Indikationsgruppen. , 2013, , 43-376.		0
1189	Umsatzver�nderungen in einzelnen Indikationsgruppen. , 2013, , 47-373.		0
1190	Mental health and criminality: A Sri Lankan perspective. Sri Lanka Journal of Psychiatry, 2013, 3, 1.	0.1	0
1192	The Culturally Competent Psychiatric Assessment. , 2013, , 794-822.		0
1193	The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication. Journal of Health Economics and Outcomes Research, 2013, 1, 54-61.	0.6	0
1195	Schizophrenia and Its Association with Biological and Environmental Factors: A Community Based Study. British Journal of Medicine and Medical Research, 2014, 4, 202-214.	0.2	0
1197	Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 9. Auflage. , 2014, , 1-91.		0
1198	Umsatzver�nderungen in einzelnen Indikationsgruppen. , 2014, , 49-376.		0
1199	Psychosis and Gender: Everything You Always Wanted to Know About Sex (and Gender) in Psychosis but Were Afraid to Ask. , 2015, , 361-387.		1
1200	Trauma Exposure, Schizophrenia Symptoms and the Stress Vulnerability Model. , 2015, , 1-20.		1
1202	Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage. , 2015, , e1-e96.		0

#	ARTICLE	IF	CITATIONS
1203	Transkulturelle Aspekte psychischer Erkrankungen. , 2015, , 1-30.		0
1204	Psychiatric diagnosis and sociodemographic characteristics of patients admitted to psychiatry clinic in a rural area. Dusunen Adam, 2015, , 8-16.	0.0	3
1206	New Age Antipsychotic: Iloperidone. Pharmacology Toxicology and Biomedical Reports, 2015, 1, 41-49.	0.0	0
1207	Serum Vitamin D Deficiency and Risk of Schizophrenia : A Case Control Study. The Egyptian Journal of Hospital Medicine, 2015, 61, 437-444.	0.0	0
1208	Depresi ³ n en pacientes con esquizofrenia ingresados en servicios de agudos del Hospital Psiqui ¹ trico de La Habana. Revista De Psicología (Peru), 2015, 33, 131-151.	0.2	0
1209	Severe Psychopathology. Autism and Child Psychopathology Series, 2016, , 301-314.	0.1	0
1210	18. Mental Disorders. , 2016, , .		0
1211	A STUDY OF STRESSORS, COPING SKILLS, AND BURDEN IN CAREGIVERS OF PATIENTS WITH SCHIZOPHRENIA. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 3741-3749.	0.1	1
1213	Analysis of TAP1333, TAP1637, TAP2379 Polymorphisms in Patients with Schizophrenia. Journal of Biomedicine, 2016, 1, .	0.0	0
1214	An Emerging Natural History in the Development, Mechanisms and Worldwide Prevalence of Major Mental Disorders. The Open Neurology Journal, 2016, 10, 149-154.	0.4	1
1215	Transkulturelle Aspekte psychischer Erkrankungen. , 2017, , 433-462.		0
1216	Sarbin [™] s Way: Markers on a Long Career Pathway in Psychology. , 2017, , 39-82.		0
1217	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. , 2017, , 1-111.		0
1220	Directly observed therapy for clozapine with concomitant methadone prescription: a method for improving adherence and outcome. BMJ Case Reports, 2017, 2017, bcr-2017-221048.	0.2	2
1223	Psychotische St [¶] rungen. , 2018, , 351-363.		1
1224	Psychosis: Schizophrenia and Related Disorders. , 2018, , 335-372.		0
1225	Psychosis and Suicide. , 2018, , 53-69.		0
1226	Plasma homocysteine in first-episode schizophrenia. Middle East Current Psychiatry, 2018, 25, 42-49.	0.5	0

#	ARTICLE	IF	CITATIONS
1228	PSÄ°KOLOJÄ° Ā-ĀžRENCÄ°LERÄ°NÄ°N ĀžÄ°ZOFRENÄ°YE YÄ-NELÄ°K TUTUMLARININ BELÄ°RLENMESÄ°: ANKARA YILDIRIM BEYAZIT ĀœNÄ°VERSÄ°TESÄ° Ā-RNEÄžÄ°. R&S - Research Studies Anatolia Journal, 2018, 1, 195-203.	0.1	0
1231	Lâ€™™apport des bases de donnÄ©es nationales dans lâ€™™Ä©pidÄ©miologie des troubles psychotiques. French Journal of Psychiatry, 2018, 1, S34-S35.	0.1	0
1234	Allgemeine Grundlagen (Modul 1). , 2019, , 1-12.		0
1235	Behandlung unter besonderen Bedingungen (Modul 4c). , 2019, , 181-254.		0
1236	Applications in Clinical Psychology. Springer Series in Synergetics, 2019, , 407-465.	0.2	0
1240	Yozgat Ā°linde Bir YÄ±l Ā°Āşerisinde Āœniversite Hastanesi Psikiyatri PolikliniÄŸine BaĀyvuran HastalarÄ±n Klinik TanÄ±larÄ± ve Sosyodemografik Verilerinin DeĀerlendirilmesi. Bozok TÄ±p Dergisi, 0, , .	0.0	1
1244	Toxoplasmosis and the risk for psychiatric disorders. Psihiatru Ro, 2019, 58 (3), 11-15.	0.0	0
1249	Animal Psychopathology. , 2020, , 1-8.		0
1251	Assessment of Family Burden of Patients Suffering from Schizophrenia-Need of the Hour. Journal of Advanced Research in Psychology & Psychotherapy, 2020, 2, 11-22.	0.0	0
1252	Persistence of Antipsychotic Use After Clozapine Discontinuation: A Realâ€World Study Across Antipsychotics. Clinical and Translational Science, 2020, 13, 1170-1177.	1.5	6
1253	Evaluation of the potential toxicity of haloperidol, clozapine and a new putative antipsychotic molecule, PT-31, in an alternative toxicity model, C. elegans. International Journal for Innovation Education and Research, 2020, 8, 502-512.	0.0	3
1254	The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts. Pharmacotherapy in Psychiatry and Neurology, 2020, 36, 107-115.	0.1	0
1255	Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 132, 1205-1213.	2.9	13
1256	Comorbidity between mood and substance-related disorders: A systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry, 2022, 56, 757-770.	1.3	14
1257	Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia. RSC Drug Discovery Series, 2020, , 175-197.	0.2	1
1258	Genetic liability in individuals at ultra-high risk of psychosis: A comparison study of 9 psychiatric traits. PLoS ONE, 2020, 15, e0243104.	1.1	3
1259	Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. International Journal of Neuropsychopharmacology, 2020, 23, 775-782.	1.0	16
1260	A Novel Genotyping Method for Detection of the Muscarinic Receptor M1 Gene rs2067477 Polymorphism and Its Genotype/Allele Frequencies in a Turkish Population. Turkish Journal of Pharmaceutical Sciences, 2020, 17, 653-658.	0.6	0

#	ARTICLE	IF	CITATIONS
1261	Voluntary and involuntary admissions with schizoaffective disorder: do they differ from schizophrenia?. Irish Journal of Psychological Medicine, 2020, , 1-8.	0.7	0
1262	Clinical Neuropharmacology. , 2021, , 103-152.		0
1264	Gender and Schizophrenia: Are Differences Biological or Social?. , 2020, , 109-127.		0
1265	Family-Led Care for People Living with Severe and Enduring Mental Illness (SEMI) in the Low-Resource Settings. , 2021, , 1363-1378.		0
1266	Impact of Non-pharmacological Interventions on Brain Structure and Function in Schizophrenia. , 2020, , 385-409.		1
1268	Maternal Immune Activation as a Risk Factor for Schizophrenia: Evidence From Preclinical and Clinical Studies. Agents and Actions Supplements, 2020, , 129-154.	0.2	2
1270	Genetic Predisposition Between COVID-19 and Four Mental Illnesses: A Bidirectional, Two-Sample Mendelian Randomization Study. Frontiers in Psychiatry, 2021, 12, 746276.	1.3	19
1271	Catatonia: demographic, clinical and laboratory associations. Psychological Medicine, 2023, 53, 2492-2502.	2.7	18
1272	Cognitive markers related to long-term remission status in Schizophrenia Spectrum Disorders. Psychiatry Research, 2020, 289, 113035.	1.7	4
1273	Positive Association of Human SHC3 Gene with Schizophrenia in a Northeast Chinese Han Population. Psychiatry Investigation, 2020, 17, 934-940.	0.7	3
1275	Morita therapy for schizophrenia: An updated meta-analysis. Asian Journal of Psychiatry, 2020, 53, 102169.	0.9	3
1276	Family-Led Care for People Living with Severe and Enduring Mental Illness (SEMI) in the Low-Resource Settings. , 2021, , 1-17.		0
1280	An insight into the understanding of 5-HTR2A variants leading to schizophrenia. Indian Journal of Medical Research, 2014, 140, 713-5.	0.4	0
1281	Transition to Psychosis: Evaluation of the First-Degree Relatives of Patients with Schizophrenia âĖŹ. Iranian Journal of Psychiatry, 2016, 11, 15-23.	0.4	4
1282	In Search of the Holy Grail: Understanding Research Success. Rand Health Quarterly, 2012, 1, 14.	0.6	2
1284	Analysis of gene polymorphism (rs11792633 C/T) and risk of schizophrenia. Molecular Biology Research Communications, 2016, 5, 45-48.	0.2	3
1285	Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia. American Health and Drug Benefits, 2016, 9, 399-410.	0.5	7
1286	Lack of Association Between Dopamine Beta-Hydroxylase (DBH) 19-bp Insertion/Deletion Polymorphism and Risk of Schizophrenia. Iranian Journal of Psychiatry, 2016, 11, 239-243.	0.4	2

#	ARTICLE	IF	CITATIONS
1287	Detection of Borna Disease Virus (BDV) in Patients with First Episode of Schizophrenia. Iranian Journal of Psychiatry, 2016, 11, 257-261.	0.4	5
1288	Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia. Shanghai Archives of Psychiatry, 2017, 29, 287-294.	0.7	2
1289	Protein-Protein Interaction Analysis of Common Top Genes in Obsessive-Compulsive Disorder (OCD) and Schizophrenia: Towards New Drug Approach Obsessive-Compulsive disorder (OCD) and Schizophrenia Comorbidity Gene Analysis. Iranian Journal of Pharmaceutical Research, 2018, 17, 173-186.	0.3	9
1290	Factors that Impact Caregivers of Patients with Schizophrenia. Current Health Sciences Journal, 2019, 45, 301-310.	0.2	0
1291	Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. BMJ Open, 2020, 10, e038013.	0.8	0
1292	Predictive waves in the autism-schizophrenia continuum: A novel biobehavioral model. Neuroscience and Biobehavioral Reviews, 2022, 132, 1-22.	2.9	24
1293	CBT-I for patients with schizophrenia and other psychotic disorders. , 2022, , 165-179.		1
1294	Rare Pathogenic Variants in Genes Implicated in Glutamatergic Neurotransmission Pathway Segregate with Schizophrenia in Pakistani Families. Genes, 2021, 12, 1899.	1.0	2
1296	Evidence for the Association between the Intronic Haplotypes of Ionotropic Glutamate Receptors and First-Episode Schizophrenia. Journal of Personalized Medicine, 2021, 11, 1250.	1.1	1
1297	The Relationships Between Childhood Abuse and Neglect, Sub-clinical Symptoms of Psychosis and Self-harm in a Non-clinical Community Sample. Journal of Child and Adolescent Trauma, 2022, 15, 605-614.	1.0	3
1298	Additional Links Between Toxoplasmosis and Psychosis. , 2022, , 111-120.		0
1299	History of Suicide Attempts and COVID-19 Infection in Veterans with Schizophrenia or Schizoaffective Disorder: Moderating Effects of Age and Body Mass Index. Complex Psychiatry, 2022, 8, 28-34.	1.3	2
1300	Isobaric tags for relative and absolute quantitation in identifying proteins for clozapine treatment response in patients with schizophrenia: A preliminary study. Taiwanese Journal of Psychiatry, 2021, 35, 140.	0.1	0
1301	The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study. SAGE Open Medicine, 2021, 9, 205031212110562.	0.7	4
1302	Regulatory Variant rs2535629 in <i>ITIH3</i> Intron Confers Schizophrenia Risk By Regulating CTCF Binding and <i>SFMBT1</i> Expression. Advanced Science, 2022, 9, e2104786.	5.6	8
1303	Explanatory Models of Illness and Psychiatric Rehabilitation: A Clinical Sociology Approach. Qualitative Sociology Review, 2010, 6, 63-80.	0.1	2
1304	Chapitre 1. Schizophr�nie(s): cliniques. , 2015, , 5-18.		0
1305	Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. BMJ Open, 2020, 10, e038013.	0.8	4

#	ARTICLE	IF	CITATIONS
1306	A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial. <i>JMIR Formative Research</i> , 2022, 6, e29154.	0.7	15
1307	Modeling and Targeting Neuroglial Interactions with Human Pluripotent Stem Cell Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1684.	1.8	6
1308	Inpatient Early Intervention for Serious Mental Illnesses Is Associated With Fewer Rehospitalizations Compared With Treatment as Usual in a High-volume Public Psychiatric Hospital Setting. <i>Journal of Psychiatric Practice</i> , 2022, 28, 24-35.	0.3	1
1310	Schizophrenia induces abnormal frequency-dependent patterns of dynamic brain network reconfiguration during an auditory oddball task. <i>Journal of Neural Engineering</i> , 2022, 19, 016033.	1.8	3
1311	ANK3 and ZNF804A intronic variants increase risk of schizophrenia in Iranian population: An association study. <i>Gene Reports</i> , 2022, 26, 101511.	0.4	1
1312	Complex chronic conditions among children born to women with schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 24-35.	1.1	6
1313	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. <i>Asian Journal of Psychiatry</i> , 2022, 69, 103007.	0.9	12
1314	Effects of Aerobic, Resistance, and Combined Exercise Training on Psychiatric Symptom Severity and Related Health Measures in Adults Living With Schizophrenia: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 753117.	1.1	13
1317	METABOLIC EFFECTS OF ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA. , 2022, , 14-16.		0
1319	Association between Tumor Necrosis factor-Alpha(<i>TNF-α</i>) polymorphisms and Schizophrenia: an updated meta-analysis. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 294-302.	1.2	2
1320	Review of Synthetic Approaches toward the Synthesis of Cariprazine, an Antipsychotic Drug. <i>Organic Process Research and Development</i> , 2022, 26, 493-507.	1.3	4
1321	EEG Microstates in Early Phase Psychosis: The Effects of Acute Caffeine Consumption. <i>Clinical EEG and Neuroscience</i> , 2022, 53, 335-343.	0.9	1
1322	Immediate and Sustained Outcomes and Moderators Associated With Metacognitive Training for Psychosis. <i>JAMA Psychiatry</i> , 2022, 79, 417.	6.0	42
1323	Geographical Variation in Mental Hospital Discharges in Greece: A Nationwide Study (1999â€“2012). <i>Psych</i> , 2022, 4, 200-214.	0.7	0
1324	Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice. <i>Psychopharmacology</i> , 2022, 239, 2263-2275.	1.5	2
1325	Craft Activities as a Meaningful Occupation among Clients with Schizophrenia in Thailand. <i>Occupational Therapy in Mental Health</i> , 2022, 38, 236-257.	0.2	1
1326	Schizophrenia: a disorder of broken brain bioenergetics. <i>Molecular Psychiatry</i> , 2022, 27, 2393-2404.	4.1	26
1327	Toward recovery in schizophrenia: Current concepts, findings, and future research directions. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 282-291.	1.0	33

#	ARTICLE	IF	CITATIONS
1328	Characteristics, Biological Activities, Synthesis, and Methods for the Determination of Brexpiprazole in Different Matrices. <i>Current Pharmaceutical Analysis</i> , 2022, 18, 765-776.	0.3	2
1329	Endosomal trafficking in schizophrenia. <i>Current Opinion in Neurobiology</i> , 2022, 74, 102539.	2.0	3
1330	The impact of cold spells on schizophrenia admissions and the synergistic effect with the air quality index. <i>Environmental Research</i> , 2022, 212, 113243.	3.7	7
1331	Adverse effects of electroconvulsive therapy. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
1332	Autism spectrum disorder and schizophrenia: An updated conceptual review. <i>Autism Research</i> , 2022, 15, 384-412.	2.1	40
1333	Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. <i>Annals of General Psychiatry</i> , 2021, 20, 56.	1.2	1
1334	Predicting time to relapse in patients with schizophrenia according to patients' relapse history: a historical cohort study using real-world data in Sweden. <i>BMC Psychiatry</i> , 2021, 21, 634.	1.1	8
1335	Deletion of Schizophrenia Susceptibility Gene <i>Ulk4</i> Leads to Abnormal Cognitive Behaviors via <i>Akt-GSK-3</i> Signaling Pathway in Mice. <i>Schizophrenia Bulletin</i> , 2022, 48, 804-813.	2.3	1
1336	Diagnostic classification of schizophrenia and bipolar disorder by using dynamic functional connectivity: An fNIRS study. <i>Journal of Neuroscience Methods</i> , 2022, 376, 109596.	1.3	6
1337	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	4.1	44
1357	How much does that cost? Examining the economic costs of crime in North America attributable to people with psychopathic personality disorder.. <i>Personality Disorders: Theory, Research, and Treatment</i> , 2023, 14, 391-400.	1.0	4
1358	Psychoeducation for Siblings of People with Severe Mental Illness. <i>Issues in Mental Health Nursing</i> , 2017, 38, 283-284.	0.6	3
1361	The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model. <i>Acta Clinica Belgica</i> , 2012, 67, 108-19.	0.5	2
1362	Distinct Brain Dynamic Functional Connectivity Patterns in Schizophrenia Patients With and Without Auditory Verbal Hallucinations. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 838181.	1.0	3
1363	Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review. <i>Health Psychology Research</i> , 2022, 10, .	0.6	0
1364	Cognitive behavioural therapy plus standard care for first episode psychosis. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
1365	Structural and Functional Deviations of the Hippocampus in Schizophrenia and Schizophrenia Animal Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5482.	1.8	18
1366	Chapitre 5. Psychoses Ã l'adolescence. , 2014, , 143-178.		0

#	ARTICLE	IF	CITATIONS
1367	SÃndrome de down e esquizofrenia: um relato de caso. Revista Debates Em Psiquiatria, 2019, 9, 46-48.	0.3	0
1368	Effect of dopamine receptor-related compounds on naive common marmosets for auditory steady state response. Journal of Neurophysiology, 2022, , .	0.9	0
1369	Animal Psychopathology. , 2022, , 307-314.		0
1372	Plasma Orexin-A Levels in Patients With Schizophrenia: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry, 2022, 13, .	1.3	1
1373	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. Health Technology Assessment, 2022, 26, 1-174.	1.3	16
1374	Social integration of people with non-psychotic mental illness over the last 2Âdecades: the widening gap in the adult population in Belgium. Social Psychiatry and Psychiatric Epidemiology, 0, , .	1.6	1
1375	New Paradigms of Old Psychedelics in Schizophrenia. Pharmaceuticals, 2022, 15, 640.	1.7	22
1376	Social barriers affecting participation in chosen instrumental activities of daily living among community-dwelling persons with schizophrenia in Rwanda. Mental Health and Social Inclusion, 2022, ahead-of-print, .	0.3	0
1378	Risk factors of deficit and non-deficit schizophrenia: Results from a cross-sectional study. Revista De PsiquiatrÃa Y Salud Mental, 2022, 15, 223-229.	1.0	5
1379	Correlation of <scp>BDNF</scp>, <scp>VEGF</scp>, <scp>TNF</scp>â€†, and <scp>S100B</scp> with cognitive impairments in chronic, medicated schizophrenia patients. Neuropsychopharmacology Reports, 2022, 42, 281-287.	1.1	11
1380	The Long Non-Coding RNA GOMAFU in Schizophrenia: Function, Disease Risk, and Beyond. Cells, 2022, 11, 1949.	1.8	9
1381	Modeling of SGLT1 in Reconstituted Systems Reveals Apparent Ion-Dependencies of Glucose Uptake and Strengthens the Notion of Water-Permeable Apo States. Frontiers in Physiology, 0, 13, .	1.3	3
1382	Transcranial Direct Current Stimulation on the Left Superior Temporal Sulcus Improves Social Cognition in Schizophrenia: An Open-Label Study. Frontiers in Psychiatry, 0, 13, .	1.3	6
1383	Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia. Brain Sciences, 2022, 12, 768.	1.1	2
1384	Effectivity of (Personalized) Cognitive Behavioral Therapy for Insomnia in Mental Health Populations and the Elderly: An Overview. Journal of Personalized Medicine, 2022, 12, 1070.	1.1	4
1385	Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. American Journal of Psychiatry, 2022, 179, 611-627.	4.0	29
1386	Schizophrenia pregnancies should be given greater health priority in the global health agenda: results from a large-scale meta-analysis of 43,611 deliveries of women with schizophrenia and 40,948,272 controls. Molecular Psychiatry, 2022, 27, 3294-3305.	4.1	8
1387	Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system. Molecular Diversity, 2023, 27, 959-985.	2.1	11

#	ARTICLE	IF	CITATIONS
1388	Familial aggregation of synaesthesia with autism (but not schizophrenia). <i>Cognitive Neuropsychiatry</i> , 2022, 27, 373-391.	0.7	3
1389	Toll-Like Receptor 4 Gene Polymorphisms and Susceptibility to Schizophrenia: A Case-Control Study. <i>Immunological Investigations</i> , 2022, 51, 2009-2024.	1.0	7
1390	Development of a Personalized Tobacco Cessation Intervention Package (PTCIP) for Persons with Schizophrenia in India. <i>Indian Journal of Psychological Medicine</i> , 2023, 45, 132-138.	0.6	2
1391	Psychobiotics: the Influence of Gut Microbiota on the Gut-Brain Axis in Neurological Disorders. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 1952-1964.	1.1	18
1396	Twin research in psychopathology. , 2022, , 337-350.		0
1397	The full spectrum of clinical stages of psychosis among mentally ill prisoners in New South Wales (NSW), Australia. <i>Psychiatry, Psychology and Law</i> , 0, , 1-18.	0.9	0
1398	Feasibility of conducting a pilot randomized control trial of a psycho-education intervention in patients with a first episode psychosis in Ugandaâ€”A study protocol. <i>PLoS ONE</i> , 2022, 17, e0268493.	1.1	0
1399	Maternal Schizophrenia and the Risk of a Childhood Chronic Condition. <i>Schizophrenia Bulletin</i> , 2022, 48, 1252-1262.	2.3	2
1400	Effects of electroconvulsive therapy on cognition and quality of life in schizophrenia. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 400-408.	0.2	1
1401	Impact of clozapine on the expression of miR-675-3p in plasma exosomes derived from patients with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2023, 24, 303-313.	1.3	7
1402	New quantification method for monitoring 18 amino acids levels in schizophrenic patients by high-performance liquid chromatography coupled to tandem quadrupole mass spectrometer. <i>Biomedical Chromatography</i> , 0, , .	0.8	2
1403	Altered asymmetries of resting-state MRI in the left thalamus of first-episode schizophrenia. <i>Chronic Diseases and Translational Medicine</i> , 2022, 8, 207-217.	0.9	2
1405	Predicting symptom response and engagement in a digital intervention among individuals with schizophrenia and related psychoses. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
1406	Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts. <i>British Journal of Psychiatry</i> , 2022, 221, 758-765.	1.7	6
1407	Maternal immune activation in rats induces dysfunction of placental leucine transport and alters fetal brain growth. <i>Clinical Science</i> , 2022, 136, 1117-1137.	1.8	9
1408	Pharmacological interventions for social cognitive impairments in schizophrenia: A protocol for a systematic review and network meta-analysis. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	4
1410	The Intellectual Structure of Research on Rural-to-Urban Migrants: A Bibliometric Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9729.	1.2	4
1411	Homoeopathic Add-On Treatment in Schizophreniaâ€”A Case Report. <i>Homopathic Links</i> , 2022, 35, 291-301.	0.1	0

#	ARTICLE	IF	CITATIONS
1412	Talking about Health: A Topic Analysis of Narratives from Individuals with Schizophrenia and Other Serious Mental Illnesses. Behavioral Sciences (Basel, Switzerland), 2022, 12, 286.	1.0	1
1413	Experience of reproductive concerns in women with schizophrenia: A descriptive phenomenological study. International Journal of Nursing Studies, 2022, 135, 104343.	2.5	2
1414	Association between sequential extreme precipitation-heatwaves events and hospitalizations for schizophrenia: The damage amplification effects of sequential extremes. Environmental Research, 2022, 214, 114143.	3.7	4
1415	Psychometric Properties of Two Tasks in the Allen Cognitive Level Screenâ€“Sixth Edition for Community-Dwelling People Living With Schizophrenia. American Journal of Occupational Therapy, 2022, 76, .	0.1	0
1416	Biological hypotheses, risk factors, and biomarkers of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 120, 110626.	2.5	26
1417	Modulating Specific Pathways In Vitro to Understand the Synaptic Dysfunction of Schizophrenia. Advances in Experimental Medicine and Biology, 2022, , 121-127.	0.8	0
1418	Measuring Psychotropic Drug Effects and Side Effects. Autism and Child Psychopathology Series, 2022, , 505-533.	0.1	0
1419	Mental Health Services in Low- and Middle-Income Countries. , 2022, , 1-16.		0
1420	Mind the gap: functional network connectivity interpolation between schizophrenia patients and controls using a variational autoencoder. , 2022, , .		0
1421	The EEG multiverse of schizophrenia. Cerebral Cortex, 2023, 33, 3816-3826.	1.6	6
1422	Protein Succinylation and Malonylation as Potential Biomarkers in Schizophrenia. Journal of Personalized Medicine, 2022, 12, 1408.	1.1	2
1423	Treatment-resistant schizophrenia: How far have we traveled?. Frontiers in Psychiatry, 0, 13, .	1.3	5
1424	Gender-related associations between psychiatric disorders and alcohol use disorder: Findings from the french â€œMental health in the general populationâ€•survey. Archives of Women's Mental Health, 2022, 25, 895-902.	1.2	2
1425	Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis. Molecular Psychiatry, 2022, 27, 5135-5143.	4.1	5
1426	Association analysis of risk genes identified by SCHEMA with schizophrenia in the Chinese Han population. Psychiatric Genetics, 2022, 32, 188-193.	0.6	3
1427	Using novel methodology to estimate the prevalence of mental disorders in British Columbia, Canada. Social Psychiatry and Psychiatric Epidemiology, 0, , .	1.6	1
1428	Inclusion of Acupuncture as an Adjunct Therapy in the Management of a Patient With Schizophrenia and Dissociative Identity Disorder: A Case Report. Journal of Chiropractic Medicine, 2022, , .	0.3	0
1429	Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation. BMC Psychiatry, 2022, 22, .	1.1	3

#	ARTICLE	IF	CITATIONS
1430	The mirror mechanism in schizophrenia: A systematic review and qualitative meta-analysis. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	3
1431	Cigarette smoking, coffee consumption, alcohol intake, and clozapine metabolism: A Mendelian randomization study. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
1432	The emerging role of long non-coding RNAs in schizophrenia. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1
1433	Integrative Brain Network and Salience Models of Psychopathology and Cognitive Dysfunction in Schizophrenia. <i>Biological Psychiatry</i> , 2023, 94, 108-120.	0.7	13
1434	Sex Differences in Cognition in Schizophrenia: What We Know and What We Do Not Know. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 463-474.	0.8	2
1435	Exploring the trend of Schizophrenia at Hiwot Fana specialized university referral hospital, Eastern, Ethiopia (2016â€“2020): A 5-year retrospective analysis. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211321.	0.7	0
1436	Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11835.	1.8	3
1437	Heterogeneity in Response to MCT and Psychoeducation: A Feasibility Study Using Latent Class Mixed Models in First-Episode Psychosis. <i>Healthcare (Switzerland)</i> , 2022, 10, 2155.	1.0	0
1439	MAOA-uVNTR variations in schizophrenia: case and control study. <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	1
1440	The effects of preventative cannabidiol in a male neuregulin 1 mouse model of schizophrenia. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	1
1441	<i>RGS3</i> and <i>IL1RAPL1</i> missense variants implicate defective neurotransmission in early-onset inherited schizophrenias. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E379-E390.	1.4	3
1442	Polygenic risk scores for schizophrenia and major depression are associated with socio-economic indicators of adversity in two British community samples. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	5
1443	The Prevalence of Self-injurious Behavior in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	2
1445	The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies. <i>Pharmacoeconomics</i> , 2023, 41, 139-153.	1.7	4
1446	Genetic evidence for association of NOTCH4 variant rs2071287 with schizophrenia susceptibility in the North Indian population. <i>Indian Journal of Psychiatry</i> , 2022, 64, 567.	0.4	0
1447	Risk factors of deficit and non-deficit schizophrenia: Results from a cross-sectional study. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2022, 15, 223-229.	0.2	0
1448	Effects of <i>Toxoplasma gondii</i> infection on cognition, symptoms, and response to digital cognitive training in schizophrenia. , 2022, 8, .		0
1449	A comparative study to determine the association of gut microbiome with schizophrenia in Zhejiang, China. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	3

#	ARTICLE	IF	CITATIONS
1450	Overlap between genetic variants associated with schizophrenia spectrum disorders and intelligence quotient: a systematic review. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E393-E408.	1.4	3
1451	The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum. <i>Aids</i> , 2023, 37, 259-269.	1.0	7
1452	Serum metabolic signatures of schizophrenia patients complicated with hepatitis B virus infection: A 1H NMR-based metabolomics study. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	0
1453	Reviewing the Potential Therapeutic Approaches Targeting the Modulation of Gastrointestinal Microflora in Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16129.	1.8	3
1454	NRG1 knockdown rescues PV interneuron GABAergic maturation deficits and schizophrenia behaviors in fetal growth restriction mice. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	2
1455	Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies. <i>Psychiatry Research</i> , 2023, 320, 114997.	1.7	3
1456	Mortality Rate in Schizophrenia. , 2023, , 303-312.		0
1457	Third-generation genome sequencing implicates medium-sized structural variants in chronic schizophrenia. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	0
1458	Meta-analysis of brain samples of individuals with schizophrenia detects down-regulation of multiple ATP synthase encoding genes in both females and males. <i>Journal of Psychiatric Research</i> , 2023, 158, 350-359.	1.5	5
1459	The impact of hazes on schizophrenia admissions and the synergistic effect with the combined atmospheric oxidation capacity in Hefei, China. <i>Environmental Research</i> , 2023, 220, 115203.	3.7	1
1460	How a point-of-care dashboard facilitates co-production of health care and health for and with individuals with psychotic disorders: a mixed-methods case study. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	1
1461	Copy Number Variations and Schizophrenia. <i>Molecular Neurobiology</i> , 2023, 60, 1854-1864.	1.9	4
1462	Mobile Mental Health Units in Heraklion Crete 2013â€“2022: Progress, Difficulties and Future Challenges. <i>Psych</i> , 2023, 5, 26-37.	0.7	1
1463	Cognitive Rehabilitation in Schizophrenia-Associated Cognitive Impairment: A Review. <i>Neurology International</i> , 2023, 15, 12-23.	1.3	1
1464	Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2023, 147, 360-372.	2.2	5
1465	Serum cortisol and insulin-like growth factor 1 levels in major depressive disorder and schizophrenia. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1466	Assessing the effectiveness and cost-effectiveness of a solution-focused resource-orientated approach (DIALOG+) to improving the quality of life for people with psychosis in India and Pakistanâ€”a cluster RCT. <i>Trials</i> , 2023, 24, .	0.7	0
1467	Association between obsessive-compulsive disorder and the risk of schizophrenia using the Korean National Health Insurance Service-National Sample Cohort: a retrospective cohort study. <i>Epidemiology and Psychiatric Sciences</i> , 2023, 32, .	1.8	0

#	ARTICLE	IF	CITATIONS
1468	Association between childhood trauma and white matter deficits in first-episode schizophrenia. <i>Psychiatry Research</i> , 2023, 323, 115111.	1.7	1
1469	Systematic review and meta-analysis of retinal microvascular caliber in bipolar disorder, major depressive disorder, and schizophrenia. <i>Journal of Affective Disorders</i> , 2023, 331, 342-351.	2.0	2
1470	Automatic detection of schizophrenia based on spatial-temporal feature mapping and LeViT with EEG signals. <i>Expert Systems With Applications</i> , 2023, 224, 119969.	4.4	3
1471	MiRNA Differences Related to Treatment-Resistant Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1891.	1.8	3
1472	The complexity of theory of mind deficit in schizophrenia: A cross-sectional analysis of baseline data from a longitudinal schizophrenia study. <i>Acta Psychologica</i> , 2023, 233, 103842.	0.7	0
1474	Psychiatric and non-psychiatric polypharmacy among older adults with schizophrenia: Trends from a population-based study between 2000 and 2016. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1475	Diminished Auditory Cortex Dynamic Range and its Clinical Correlates in First Episode Psychosis. <i>Schizophrenia Bulletin</i> , 0, , .	2.3	1
1477	Psychosocial functioning and associated socio-environmental factors of children with severe mental illness: findings from the tertiary mental health center in India. <i>Social Work in Mental Health</i> , 2023, 21, 243-268.	0.7	3
1478	The Relationship Between Socioeconomic Status and Risk of Schizophrenia. , 2022, , 1644-1651.		0
1479	Art Making in Schizophrenia: A Vision Science Perspective. <i>Current Clinical Neurology</i> , 2023, , 113-142.	0.1	0
1480	Vitamin D supplementation is effective for olanzapine-induced dyslipidemia. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1481	Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. <i>Psychiatry Research</i> , 2023, 322, 115138.	1.7	0
1482	Factors Contributing to Risk of Persistence of Positive and Negative Symptoms in Schizophrenia during Hospitalization. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4592.	1.2	1
1483	Practitioner Review: Psychosis in children and adolescents. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2023, 64, 980-988.	3.1	4
1485	Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review. <i>Schizophrenia Research</i> , 2023, , .	1.1	1
1486	The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders. <i>Advances in Neurobiology</i> , 2023, , 255-285.	1.3	0
1489	Real-life functioning in women with schizophrenia living in residential facilities: Gender-based comparison. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	1
1490	Children with Early-Onset Psychosis Have Increased Burden of Rare GRIN2A Variants. <i>Genes</i> , 2023, 14, 779.	1.0	2

#	ARTICLE	IF	CITATIONS
1491	Reprioritising global mental health: psychoses in sub-Saharan Africa. <i>International Journal of Mental Health Systems</i> , 2023, 17, .	1.1	1
1493	Beyond the Binary: Gender Inclusivity in Schizophrenia Research. <i>Biological Psychiatry</i> , 2023, 94, 543-549.	0.7	3
1494	The synaptic hypothesis of schizophrenia version III: a master mechanism. <i>Molecular Psychiatry</i> , 2023, 28, 1843-1856.	4.1	20
1495	Gut-brain axis volatile organic compounds derived from breath distinguish between schizophrenia and major depressive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2023, 48, E117-E125.	1.4	3
1497	Offenders and non-offenders with schizophrenia spectrum disorders: Do they really differ in known risk factors for aggression?. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	3
1498	Schizophrenia, Human Leukocyte Antigen (HLA), and Herpes Viruses: Immunogenetic Associations at the Population Level. <i>Neuroscience Insights</i> , 2023, 18, 263310552311664.	0.9	2
1499	Incidence and Persistence of Psychotic Experiences in the General Population: Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2023, 49, 1007-1021.	2.3	7
1500	Approach to schizophrenia. <i>Internal Medicine Journal</i> , 2023, 53, 473-480.	0.5	2
1507	Maternal Medical Disorders of Fetal Significance. , 2024, , 82-98.e4.		0
1519	Application of Genetic Algorithm in Predicting Mental Illness: A Case Study of Schizophrenia. <i>Springer Tracts in Nature-inspired Computing</i> , 2023, , 161-183.	1.2	0
1536	Neurodevelopmental disorders. , 2023, , .		0
1545	Schizophrenia and Other Primary Psychotic Disorders. , 2023, , 1-59.		0
1553	Mental Health Services in Low- and Middle-Income Countries. , 2023, , 933-948.		0
1556	Pharmacological update of mirtazapine: a narrative literature review. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	0
1560	19. Mental Disorders. , 2023, , .		0
1566	Umbrella Review of the Global Prevalence of Conduct Disorder in Children and Adolescents. <i>Psychiatric Quarterly</i> , 2024, 95, 173-183.	1.1	1
1591	On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 0, , .	4.1	0
1596	Mental health: Morbidity and impact. , 2024, , .		0

#	ARTICLE	IF	CITATIONS
1602	â€˜Psychoticâ€™ Disorders. , 2024, , 230-244.		0